使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning. My name is Shawn, and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant third-quarter 2015 earnings conference call.
早安。我叫 Shawn,今天將擔任本次電話會議的接線員。此刻,我謹代表公司歡迎各位參加 Valeant 2015 年第三季財報電話會議。
(Operator Instructions)
(接線員指示)
Thank you. Laurie Little, Head of Investor Relations, please go ahead.
謝謝。投資人關係主管 Laurie Little,請開始。
- Head of IR
- Head of IR
Thank you, Shawn. Good morning, everyone, and welcome to Valeant's third-quarter financial results conference call, where we will be discussing both our financial results and other matters. Participating on today's call are J. Michael Pearson, Chairman and Chief Executive Officer; Rob Rosiello, Chief Financial Officer; Dr. Ari Kellen, Company Group Chairman; and Anne Whitaker, Company Group Chairman. In addition to a live webcast, a copy of today's live presentation can be found on our website under the Investor Relations section.
謝謝你,Shawn。各位早安,歡迎參加 Valeant 第三季財務結果電話會議;我們將討論財務結果及其他事項。今天與會者包括:董事長兼執行長 J. Michael Pearson;財務長 Rob Rosiello;公司集團主席 Ari Kellen 博士;以及公司集團主席 Anne Whitaker。除即時網路直播外,今日即時簡報的副本可於本公司網站「投資人關係」專區取得。
Before we begin, our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation, as it contains important information.
在開始之前,今天的簡報包含前瞻性資訊。請各位花點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。
In addition, this presentation contains non-GAAP financial measures. For more information about non-GAAP financial measures, please refer to slide 1. Non-GAAP financial reconciliations can be found in the press release issued earlier today and posted on our website.
此外,本簡報包含非 GAAP 財務衡量指標。關於非 GAAP 財務衡量指標的更多資訊,請參閱投影片 1。非 GAAP 財務調節表可於今日稍早發布並已張貼於本公司網站的新聞稿中查閱。
Finally, the financial guidance in this presentation is effective only as of today, and it is our policy to update or affirm guidance only through broadly disseminated public disclosure. With that, I will turn the call over to Mike.
最後,本簡報中的財務指引僅於今日有效;本公司政策為僅透過廣泛公開揭露來更新或確認指引。接下來我把電話交給 Mike。
- Chairman and CEO
- Chairman and CEO
Thank you, Laurie. Good morning, everyone, and thank you for joining us. We are pleased to report exceptional results for our third quarter. We once again exceeded both top-line and bottom-line guidance, and realized our fifth consecutive quarter of greater-than-10% same-store organic growth.
謝謝你,Laurie。各位早安,感謝各位加入。我們很高興報告第三季取得卓越的成果。我們再次超越營收與獲利指引,並連續第五季達成同店有機成長超過 10%。
This outperformance absorbs the negative foreign exchange impact of $172 million in revenues and $0.13 cash EPS, and is primarily driven by the performance of our US businesses, particularly the stellar execution in both dermatology and contact lenses. Our dermatology portfolio is now performing at a $1.9 billion annual run rate. And our US contact lens business has grown 46% on an annual basis since we closed the Bausch + Lomb acquisition in August of 2013.
這項優於預期的表現吸收了外匯帶來的負面影響:營收減少 1.72 億美元、現金 EPS 減少 0.13 美元;主要由美國業務表現所驅動,尤其是皮膚科與隱形眼鏡業務的出色執行。我們的皮膚科產品組合目前年化營收運行率達 19 億美元。自 2013 年 8 月完成 Bausch + Lomb 併購以來,我們的美國隱形眼鏡業務按年計已成長 46%。
We also realized strong results in several key geographies outside the US, notably China, which saw 23% organic growth, South Korea at 15% organic growth, and Mexico with over 10% organic growth. We continue to see our Salix integration exceeding expectations following the regulatory approval for the Xifaxan IBS-D indication in May, and we recently launched both our unbranded and branded DTC campaigns. Other brands within the sales portfolio are also showing strong growth. Finally, Salix inventory levels have been reduced to approximately 8 to 10 weeks.
我們在美國以外的幾個關鍵地區也取得強勁成果,尤其是中國有機成長 23%、南韓有機成長 15%,以及墨西哥有機成長超過 10%。在 5 月取得 Xifaxan IBS-D 適應症的監管核准後,我們持續看到 Salix 的整合進度超出預期,且近期已同時推出無品牌與有品牌的 DTC(直接面向消費者)行銷活動。銷售產品組合中的其他品牌也展現強勁成長。最後,Salix 的庫存水位已降至約 8 至 10 週。
This quarter, we also saw continued weakness in both western Europe and eastern Europe across all lines of our Business. We are taking steps to reignite the growth in these markets in 2016.
本季我們也看到西歐與東歐在公司各業務線上持續疲弱。我們正採取措施,於 2016 年重新點燃這些市場的成長動能。
On the business development front, eight deals were signed in Q3, and all are closed as of today. We previously announced Amoun, Commonwealth Labs, Eyegate, Humax and Unilens on our Q2 earning call. Since that call, we have signed and closed brodalumab, Sprout and Synergetics.
在業務開發方面,第三季簽署了 8 筆交易,且截至今日皆已完成交割。我們先前已在第二季財報電話會議中宣布 Amoun、Commonwealth Labs、Eyegate、Humax 與 Unilens。自該次電話會議以來,我們已簽署並完成交割 brodalumab、Sprout 與 Synergetics。
Based on our strong base performance, and despite the genericization of Targretin and Xenazine, we delivered GAAP cash flow of $737 million, with a 90% cash conversion. For the quarter, our total revenues were $2.8 billion, an increase of 36% over the prior year, largely driven by the exceptionally strong growth in many of our US businesses which offset negative headwinds from FX. Adjusting for the negative FX of $172 million, revenue grew 44% over Q3 2014.
基於強勁的基本面表現,且儘管 Targretin 與 Xenazine 進入學名藥化,我們仍實現 GAAP 現金流 7.37 億美元,現金轉換率為 90%。本季總營收為 28 億美元,較去年同期成長 36%,主要由多項美國業務的極為強勁成長所帶動,抵銷了外匯的不利因素。若調整外匯帶來的 1.72 億美元負面影響,營收較 2014 年第三季成長 44%。
Cash EPS was $2.74, an increase of 30% over the prior year, which includes the negative impact of $0.13 from the strengthening US dollar. Adjusted for FX, cash EPS grew 36% over Q3 2014.
現金 EPS 為 2.74 美元,較去年同期成長 30%,其中包含美元走強帶來的 0.13 美元負面影響。若調整外匯因素,現金 EPS 較 2014 年第三季成長 36%。
Our overall same-store total Company organic growth was 13% for the quarter. The exceptional growth of our US businesses was complemented by many of our Asian and Latin American emerging markets. Our same-store sales organic growth for the entire Company is 15% year to date, well above guidance. Our overall pro forma total Company organic growth, including the Salix and other acquisitions, is 17% year to date.
本季整體同店公司有機成長為 13%。美國業務的卓越成長,並由多個亞洲與拉丁美洲新興市場的表現相互輝映。截至目前為止,公司整體同店銷售有機成長為 15%,明顯高於指引。整體公司按備考口徑(包含 Salix 與其他併購)之有機成長截至目前為止為 17%。
Although we stated last quarter that we will not be reporting separate B+ L organic results going forward, I thought it was important to include on today's call, given the softness in our US ophthalmology Rx business unit this quarter. The negative 3% growth for ophthalmology Rx was mainly due to a supply outage of legacy Valeant's Macugen product. Our US B+ L ophthalmology business was essentially flat this quarter. Overall, Bausch + Lomb organic growth in Q3 was 7% in the US and 10% in Asia, but globally was 5% due to our weakness in Europe.
雖然我們在上季表示未來將不再單獨揭露 B+L 的有機成長結果,但鑑於本季美國眼科處方藥(Rx)事業單位表現偏弱,我認為有必要在今天的電話會議中納入說明。眼科處方藥 -3% 的成長主要是由於 Valeant 既有產品 Macugen 供應中斷。我們的美國 B+L 眼科業務本季基本持平。整體而言,Bausch + Lomb 第三季有機成長在美國為 7%、在亞洲為 10%,但由於歐洲疲弱,全球為 5%。
In response to our shareholders, we are now expanding our quarterly disclosure to include the top 30 products in our portfolio. The top 30 worldwide products represented 54% of total quarter revenue. Our top 30 products delivered organic same-stores growth of 30% for the quarter.
為回應股東需求,我們現在擴大季度揭露內容,納入產品組合中前 30 大產品。全球前 30 大產品占本季總營收的 54%。前 30 大產品本季同店有機成長達 30%。
A couple of important note: First, Jublia scripts at a 4 ml equivalent grew 28% sequentially from Q2 2015 to Q3 2015, while revenue only grew 4%. This is primarily due to an approximately $10 million reduction in wholesaler inventory due to a stocking of the 8 ml SKU in Q2, coupled with a shift in Jublia sales from the traditional wholesaler channels towards our specialty network where inventory is held on a consignment basis. We should see revenue growth more closely matching script growth next quarter.
有幾點重要說明:第一,Jublia 以 4 ml 等量計的處方量,從 2015 年第二季到第三季按季成長 28%,但營收僅成長 4%。這主要是因為第二季備貨 8 ml SKU 後,批發商庫存約減少 1,000 萬美元,加上 Jublia 銷售從傳統批發通路轉向我們的專科網路(庫存採寄售方式持有)。我們預期下季營收成長將更貼近處方量成長。
Second, 12 of our top 30 products are global and, therefore, had depressed sales compared to prior periods due to the negative headwinds from foreign exchange. As a reminder, Glumetza will lose its patent protection in February 2016, and will fall out of the list in 2016.
第二,我們前 30 大產品中有 12 項為全球性產品,因此相較於先前期間,因外匯不利因素而使銷售表現受到壓抑。提醒各位,Glumetza 將於 2016 年 2 月失去專利保護,並將在 2016 年自該名單中移除。
We are pleased with the recent DTC campaign for Xifaxan that was launched in September with unbranded ads, and is now out in full force with the branded marketing materials. Scripts were up 15% on a sequential quarterly basis and 25% over the prior year.
我們對近期於 9 月推出的 Xifaxan DTC 行銷活動感到滿意,先以無品牌廣告啟動,目前已全面搭配有品牌的行銷素材強力推廣。處方量按季成長 15%,較去年同期成長 25%。
Other products in the sales portfolio also saw strong growth, with Uceris up 20%, Relistor scripts up 36%, and Apriso up 7% year over year. Ruconest was up 29% on a sequential basis from last quarter. Inventory levels have been reduced to approximately 8 to 10 weeks, and we expect to reach our target of four to six weeks by the end of the year.
銷售產品組合中的其他產品也呈現強勁成長,Uceris 成長 20%、Relistor 處方量成長 36%,Apriso 較去年同期成長 7%。Ruconest 較上季按季成長 29%。庫存水位已降至約 8 至 10 週,我們預期在年底前達到 4 至 6 週的目標。
Moving on to Sprout: The team at Sprout had a very exciting last couple weeks, as the field force was trained and Addyi was officially launched this past weekend. We have 148 reps and 8 MSLs in the field. We are launching these in the package insert, and will be submitting our marketing materials to OPDP shortly. We are not planning on any DTC at this time. We are also excited that Cindy Whitehead has agreed to remain as CEO.
接著談 Sprout:Sprout 團隊在過去幾週相當振奮,因為外勤團隊已完成訓練,且 Addyi 已於上週末正式上市。我們在外勤共有 148 位業務代表與 8 位醫藥科學聯絡員(MSL)。我們將在藥品仿單(package insert)中推出這些內容,並將於近期把行銷素材提交給 OPDP。目前我們不規劃進行任何 DTC(直接面向消費者)行銷。我們也很高興 Cindy Whitehead 已同意續任執行長(CEO)。
Many of you have asked about the performance in our emerging markets, specifically China, Russian and Brazil. China continues to do well, with 23% year-over-year organic growth, which we will discuss on the next slide.
許多人詢問我們在新興市場的表現,特別是中國、俄羅斯與巴西。中國持續表現良好,有機成長年增 23%,我們將在下一張投影片討論。
Our Russian business has had a difficult first three quarters of the year, and was basically flat in constant dollars compared to 2015 over this time frame. This has been compounded by the sharp drop in the ruble versus the US dollar. This is largely attributable to the economic slowdown of the Russian pharmaceutical market. We are cautiously optimistic looking forward, as our Business has recently returned to growth on a local-currency basis.
我們在俄羅斯的業務今年前三季表現艱難,以固定匯率計算,與 2015 年同期相比基本持平。此外,盧布兌美元大幅下跌也使情況更加惡化。這主要歸因於俄羅斯製藥市場的經濟放緩。展望未來我們審慎樂觀,因為我們的業務近期已在當地貨幣基礎上恢復成長。
The Brazil and Argentina business has been our most difficult set of businesses in 2015 due to the continuing devaluation of the real and the peso. The FX outlook remains poor. Fortunately, these businesses currently generate only $0.03 to $0.04 to our cash EPS on a full-year basis.
由於雷亞爾與披索持續貶值,巴西與阿根廷業務是我們 2015 年最艱難的一組業務。外匯(FX)展望仍然不佳。所幸,這些業務目前以全年計僅對我們的現金 EPS 貢獻約 0.03 至 0.04 美元。
Moving back to China: Many of you have raised questions regarding the health of our business in China, given the country's current economic challenges. We continue to see very strong growth in our business in China, with 23% organic growth in the quarter. We price our products to appeal to the middle class, and the vast majority of our business is consumer cash pay. We have a leading market share position in contact lenses, and we continue to gain share.
回到中國:鑑於中國目前的經濟挑戰,許多人對我們在中國業務的健康狀況提出疑問。我們在中國的業務仍持續呈現非常強勁的成長,本季有機成長 23%。我們的產品定價以吸引中產階級為主,而我們絕大多數業務為消費者自費(現金支付)。我們在隱形眼鏡市場居於領先市占地位,且持續提升市占。
It is interesting to note that 90% of all our products sold in China are manufactured outside of China, including at our US plants in Rochester, New York, and Greenville, South Carolina. Finally, we are expanding our Chinese portfolio to enter skincare and aesthetics with CeraVe and other products. This will provide another platform for future growth.
值得注意的是,我們在中國銷售的所有產品中,有 90% 是在中國境外製造,包括我們位於美國紐約州羅徹斯特(Rochester)與南卡羅來納州格林維爾(Greenville)的工廠。最後,我們正擴充中國產品組合,透過 CeraVe 與其他產品進入護膚與醫美領域。這將為未來成長提供另一個平台。
Before I turn the call over to Rob, I wanted to provide a quick update on a number of R&D milestones. We have recently received the Phase 2 data for the FSD trial for rifaximin, and it failed. We are currently studying the signals to determine whether or not to pursue a new program at different dosages.
在把電話會議交給 Rob 之前,我想先快速更新幾項研發里程碑。我們近期收到 rifaximin 用於 FSD 試驗的第二期(Phase 2)數據,但結果失敗。我們目前正在研究相關訊號,以判斷是否要在不同劑量下推進新的計畫。
Our Phase 3 program, IDP-118 for psoriasis, is well under way. We expect the efficacy and safety trials to read out by Q2 next year, and would expect to file Q3 2016. We expect to submit our NDA filing for broda in November. We also expect to begin the alcohol studies for Addyi later this quarter.
我們的第三期(Phase 3)計畫 IDP-118(治療乾癬)進展順利。我們預期療效與安全性試驗將於明年第二季(Q2)讀出結果,並預期於 2016 年第三季(Q3)提交申請。我們預期將於 11 月提交 broda 的 NDA 申請。我們也預期在本季稍晚開始 Addyi 的酒精交互作用研究。
Now let me turn the call over to Rob to discuss this quarter's financials.
現在我把電話會議交給 Rob,請他說明本季財務表現。
- CFO
- CFO
Thank you, Mike. Beginning on slide 12, our revenue of $2.8 billion approached the top end of our guidance, despite a negative impact of approximately $30 million since the guidance we provided during our Q2 earnings call. This is primarily driven by the outperformance of our US businesses, including dermatology and contact lens.
謝謝你,Mike。從第 12 張投影片開始,本季營收 28 億美元接近我們財測指引的上緣,儘管相較於我們在第二季(Q2)法說會提供的指引,約有 3,000 萬美元的負面影響。這主要由美國業務表現優於預期所帶動,包括皮膚科與隱形眼鏡。
Our cost of goods sold improved to 22% in the third quarter, primarily due to the continued growth in dermatology, as well as the acquisition of Salix, and the ramp-up and yield improvement in our contact lens manufacturing. This resulted in overall improved gross margins of 78%. We expect our gross margins to approach 80% in the fourth quarter, driven by continued growth in our dermatology and Salix businesses, the launch of Addyi, and decreased sales of Xenazine.
第三季銷貨成本占比改善至 22%,主要受惠於皮膚科業務持續成長、收購 Salix,以及隱形眼鏡製造的產能爬坡與良率提升。因此整體毛利率改善至 78%。我們預期第四季毛利率將接近 80%,動能來自皮膚科與 Salix 業務持續成長、Addyi 上市,以及 Xenazine 銷售下滑。
SG&A was in line with the previous year at 24%, and improved by 1 point from last quarter on an overall basis, despite increased costs associated with our launch initiatives. In the third quarter, we spent approximately $45 million in DTC advertising supporting Jublia, Onexton, Luzu and Xifaxan, as compared to $60 million in the second quarter. The sequential decrease is due to the seasonality of our DTC campaigns and typical reduced spending in the summer months. The overall SG&A improvement was also driven by growth from Salix. R&D was $102 million in the quarter, an increase of approximately 26% relative to Q2, reflecting our continued investment in legacy Valeant programs, including IDP-118 for psoriasis, other late-stage derm programs, a range of surgical programs, and continued development of new contact lenses.
SG&A 與前一年持平為 24%,整體而言較上季改善 1 個百分點,儘管我們的上市推動計畫相關成本增加。第三季我們在支援 Jublia、Onexton、Luzu 與 Xifaxan 的 DTC 廣告上支出約 4,500 萬美元,相較第二季為 6,000 萬美元。此一季對季下降主要因 DTC 活動的季節性,以及夏季月份通常會降低支出。整體 SG&A 的改善也受 Salix 成長所帶動。本季研發(R&D)費用為 1.02 億美元,較第二季增加約 26%,反映我們持續投資於既有 Valeant 計畫,包括乾癬用 IDP-118、其他後期皮膚科計畫、一系列外科手術相關計畫,以及新型隱形眼鏡的持續開發。
Our GAAP cash flow this quarter was $737 million. Excluding Q4 2013, the one quarter where we had an investment gain from the Allergan transaction, the third quarter represents the highest GAAP cash flow that Valeant has achieved. We also achieved our target of 90% cash conversion this quarter, a significant improvement from the second quarter. Given the recent acquisitions of Sprout and Amoun, as well as historical Q4 working capital trends, we expect Q4 cash conversion to be less than Q3.
本季 GAAP 現金流為 7.37 億美元。若排除 2013 年第四季(Q4 2013)—當季我們因 Allergan 交易而有投資收益—第三季是 Valeant 迄今達成的最高單季 GAAP 現金流。我們本季也達成 90% 的現金轉換率目標,較第二季顯著改善。考量近期收購 Sprout 與 Amoun,以及歷史上第四季營運資金的趨勢,我們預期第四季現金轉換率將低於第三季。
Net sales from Salix were $461 million in the third quarter, a significant increase from the second quarter, reflecting the progress we are making in inventory drawdown, as well as the uptake from the FDA approval for IBS-D in May. We began the quarter with total channel inventories of approximately 3 to 3.5 months on hand, and are now at approximately 2 to 2.5 months at the end of the quarter. We remain on track to reduce total channel inventories to 1 to 1.5 months by the end of the year. Our estimates of total channel inventories are based on actual data received from the big three wholesalers, as well as estimates of remaining inventory at smaller distributors. We expect revenues attributable to Salix will be approximately $600 million in the fourth quarter, and approximately $1.35 billion for 2015. We continue to take a conservative approach to our sales expectations until this business is completely normalized.
第三季 Salix 的淨銷售額為 4.61 億美元,較第二季大幅增加,反映我們在通路去化庫存方面的進展,以及 FDA 於 5 月核准 IBS-D 適應症後的需求提升。本季初我們的通路總庫存約為 3 至 3.5 個月,目前在季末約為 2 至 2.5 個月。我們仍按計畫在年底前將通路總庫存降至 1 至 1.5 個月。我們對通路總庫存的估計係基於三大批發商提供的實際數據,以及對較小型經銷商剩餘庫存的估算。我們預期第四季歸因於 Salix 的營收約為 6 億美元,2015 年全年約為 13.5 億美元。在該業務完全正常化之前,我們對銷售預期仍將採取保守作法。
In terms of balance sheet, we ended the quarter with a strong liquidity position through a combination of $1.5 billion undrawn revolver and $1.4 billion of cash on hand. Since quarter end, we have closed several acquisitions, and used a combination of cash and revolver to fund these transactions. We expect our revolver draw to approach zero by year end. Our net debt to pro forma adjusted EBITDA ratio was approximately 5.3 times, and we remain committed to reducing that ratio to below 4 times by the end of 2016. We are committed to debt paydowns in excess of mandatory amortizations required by our term loans.
就資產負債表而言,本季末我們透過 15 億美元未動用循環信貸(revolver)與 14 億美元現金部位的組合,維持強勁的流動性。自季末以來,我們已完成數項收購,並以現金與循環信貸的組合為交易提供資金。我們預期年底前循環信貸動用額將接近零。我們的淨負債對備考調整後 EBITDA 比率約為 5.3 倍,我們仍致力於在 2016 年底前將該比率降至 4 倍以下。我們承諾進行超過定期貸款所要求之強制攤還額度的額外償債。
As we stated in our press release, we are increasing our 2015 guidance for the fourth quarter and the full year. Fourth-quarter guidance will now be revenues of $3.25 billion to $3.45 billion, and cash EPS guidance of $4 to $4.20. Full-year revenue guidance for 2015 will be $11 billion to $11.2 billion in revenue, and cash EPS guidance will be $11.67 to $11.87. Full-year adjusted cash flow from operations is expected to be over $3.35 billion.
如同我們在新聞稿中所述,我們正在上調2015年第四季及全年指引。第四季指引現為營收32.5億至34.5億美元,現金EPS指引為4.00至4.20美元。2015年全年營收指引為110億至112億美元,現金EPS指引為11.67至11.87美元。全年經調整營運活動現金流預期將超過33.5億美元。
In April, we provided a 2016 outlook that included a $7.5 billion 2016 EBITDA expectation. We remain very comfortable with that number and expect to exceed it. While we have identified and incorporated some headwind adjustments, such as continued FX erosion and new expectations for future pricing environment, we also have completed several new transactions that provide upside in addition to the continued momentum and outperformance of our base business. We expect that organic growth will be approximately 10% in Q4, and we expect double-digit organic growth in 2016. We will provide our full 2016 guidance in early January.
在4月,我們提供了2016年展望,其中包含2016年EBITDA預期為75億美元。我們對該數字仍然非常有信心,並預期將超越它。雖然我們已辨識並納入一些逆風調整,例如持續的匯率侵蝕以及對未來定價環境的新預期,但我們也已完成數筆新交易,除基礎業務持續的動能與優於預期表現外,亦帶來額外上行空間。我們預期第四季有機成長約為10%,並預期2016年有機成長將達雙位數。我們將於1月初提供完整的2016年指引。
- Chairman and CEO
- Chairman and CEO
Based on recent acquisitions and other external events, many of you have been asking if our strategy has changed. Our mission remains the same as it always has. We will always put patients and physicians first, while taking our responsibility for our employees and communities we do business in equally importantly. We also know who our owners are. We listen to you, and work hard for you every day.
基於近期收購及其他外部事件,你們許多人一直在詢問我們的策略是否已改變。我們的使命一如既往,始終不變。我們將永遠把病患與醫師放在第一位,同時也同等重視我們對員工以及我們營運所在社區的責任。我們也清楚誰是我們的所有人。我們傾聽各位的意見,並每天為各位努力工作。
Our focus also remains the same. We concentrate on high-growth markets, both therapeutically and geographically. We prefer durable products sold to concentrated specialist populations where physician education matters. We focus on products where consumer pay or commercial reimbursement is significant. And finally, we are committed to remain diversified, where no one product or small set of products disproportionately impacts our earnings.
我們的重點也維持不變。我們專注於高成長市場,無論在治療領域或地理區域皆然。我們偏好銷售給高度集中的專科族群、且醫師教育至關重要的耐久型產品。我們聚焦於消費者自付或商業保險給付占比顯著的產品。最後,我們致力於維持多元化,使任何單一產品或少數產品不會對我們的獲利造成不成比例的影響。
What has changed is that our portfolio has shifted over time to newer and higher growth products, making pricing a smaller part of our growth looking forward. Given the evolution of our product mix, coupled with the recent events, it is likely that we will pursue fewer, if any, transactions that are focused on mispriced products.
改變之處在於,我們的產品組合隨時間轉向更新且更高成長的產品,使得定價在未來成長中的占比變小。鑑於我們產品組合的演變,加上近期事件,我們很可能會追求較少、甚至不再追求以「定價錯置」產品為重點的交易。
Now let me shift to some modifications to our strategy. First, our Neuro and Other portfolio, which is dependent on price, will represent approximately 10% of our revenues in 2016, and will continue to shrink as a percentage of the Company. We have and are seriously considering spinning off or selling this piece of our Business. Second, due to our increasing success in internal R&D, especially in the areas of dermatology, contact lenses, surgical and OTC products, internal R&D will become more of a focus. Third, if our stock price remains at current levels, share repurchases will be seriously considered.
現在讓我轉到我們策略的一些調整。第一,我們依賴價格的神經科與其他(Neuro and Other)產品組合,於2016年將約占我們營收的10%,且占公司比重將持續縮小。我們已經並正嚴肅考慮將這部分業務分拆或出售。第二,隨著我們在內部研發(R&D)方面日益成功,特別是在皮膚科、隱形眼鏡、手術及OTC產品領域,內部研發將成為更重要的重點。第三,若我們股價維持在目前水準,將嚴肅考慮進行庫藏股回購。
My final note would be that we have always believed that any company's strategy must be agile and flexible in order to navigate in an ever-changing world. During my 23 years at McKinsey, we found that companies that were successful over long periods of time had one thing in common. They were willing to move in and out of geographic and business areas over time, and they have modified and changed their strategy as the environment changed. We plan to be one of these companies.
我最後想說的是,我們一直相信,任何公司的策略都必須敏捷且具彈性,才能在不斷變化的世界中前行。在我於麥肯錫(McKinsey)的23年期間,我們發現長期成功的公司都有一個共同點。它們願意隨時間進出不同的地理與業務領域,並會隨著環境變化而調整與改變其策略。我們計畫成為這樣的公司之一。
With the turmoil over the past few weeks from both governmental and media scrutiny, and erroneous research reports, we thought it would be useful if we addressed your questions up front. You can clearly see the questions on the slide, so I won't read each one, but let's move on to the answers.
鑑於過去幾週來自政府與媒體審視,以及錯誤研究報告所造成的動盪,我們認為若能先行回應各位的問題會很有幫助。各位可以在投影片上清楚看到問題,因此我不會逐一朗讀,讓我們直接進入答案。
Valeant's price-volume growth: In the 8-K we furnished a few years ago, we tried to lay out our various business units, and the impact price has had on them. Contrary to what is reflected in the media and certain research reports, our Business is not 100% pharmaceuticals. Breaking down the Business into ex-US, US devices and consumer, US brand pharmaceuticals, and US generics, one gets a much better picture of our business breakdown.
Valeant的價格—數量成長:在我們幾年前提交的8-K中,我們嘗試說明各個事業單位,以及價格對它們造成的影響。與媒體及某些研究報告所呈現的相反,我們的業務並非100%為製藥。將業務拆分為美國以外(ex-US)、美國器材與消費品、美國品牌藥,以及美國學名藥後,能更清楚地看出我們的業務結構。
For our 2015 year to date, you can see that, although price did play a part in our branded pharmaceutical unit's growth, which accounts for roughly 43% of our revenue, revenue has grown almost 20% -- volume has grown almost 20%. In the remaining 57% of our Business, price does not play much of a role. In the end, of the 16% same-store organic growth we have realized so far across our entire portfolio this year, our price-volume mixture was roughly 50/50.
就我們2015年迄今(year to date)的表現而言,你可以看到,雖然價格確實在我們的品牌藥事業單位成長中扮演了一部分角色(該單位約占我們營收的43%),但營收成長接近20%——銷量也成長接近20%。在其餘57%的業務中,價格並未扮演太大角色。總結而言,今年迄今我們在整體產品組合所實現的16%同店有機成長中,價格與數量的組合約為50/50。
Focusing on our US branded pharmaceutical portfolio, you can see that Valeant's price-volume mix has changed over time. In 2014, we had organic growth of 20%, with volume contributing 8% and price contributing 12%. Year to date in 2015, our organic growth has increased to 41%, with volume contributing 17%. For this last quarter, volume growth has increased to 19%. You can clearly see this trend in the past seven quarters, as volume growth is accelerating, and our average net realized price per script peaking in the fourth quarter of 2014 and slowly declining in 2015. It is important to note that we realize only approximately $300 in revenues for each 30-day prescription product that we sell.
聚焦於我們的美國品牌藥產品組合,你可以看到Valeant的價格—數量組合隨時間已發生變化。2014年,我們的有機成長為20%,其中數量貢獻8%,價格貢獻12%。2015年迄今,我們的有機成長提高至41%,其中數量貢獻17%。在最近一季,數量成長已提高至19%。你可以在過去七個季度清楚看到此趨勢:數量成長正在加速,而我們每張處方的平均淨實現價格在2014年第四季達到高峰,並於2015年緩步下滑。需要強調的是,我們每售出一項30天用量的處方產品,實際僅約實現300美元的營收。
Slide 24 bridges the price-volume dynamic for the third quarter from the previous year, with 19% of our growth in the US branded portfolio coming from volume and 15% from price. It is important to note that growth from price where a generic alternative is not available accounts for less than $75 million a quarter.
投影片24將第三季相較前一年的價格—數量動態串接起來,其中美國品牌藥產品組合的成長有19%來自數量、15%來自價格。需要注意的是,在沒有學名藥替代品的情況下,由價格帶來的成長每季合計不到7,500萬美元。
As most of the commentary around price centers on the wholesale price or list price, we wanted to provide a more clear picture on what Valeant actually realizes from a price action, which is considerably different than what has been portrayed. If you look at the top 10 dermatology products, which represent approximately 62% of our dermatology portfolio, we took, on average, a 14% gross price increase on these products this year, yet we realized less than a 2% price increase on a net basis. Doing the same exercise for ophthalmology, you can see we realized a little bit more of price, but all these products were only raised 10% on a gross basis.
由於多數關於價格的評論聚焦在批發價或牌價(list price),我們希望更清楚呈現Valeant在採取價格行動後實際能實現的金額,這與外界描繪的情況有相當差異。若你看皮膚科前10大產品(約占我們皮膚科產品組合的62%),我們今年對這些產品平均調升14%的毛價格(gross price),但以淨額(net)計算,我們實現的價格上升不到2%。對眼科做同樣的分析,你可以看到我們在價格上實現得稍多一些,但這些產品在毛額基礎上也僅上調10%。
Turning to our US Neuro and Other portfolio, a portfolio that is predominantly made up of legacy products from acquisitions made over the years, our year-to-date volume decline is 7% over that time period. We realized 30% on a net price basis. It is important to note that 61% of this portfolio has generic alternatives in the market, providing doctors and patients with lower-cost alternatives. Going forward, this portfolio will represent a smaller and smaller portion of our US business. We expect it to be approximately 10% of the portfolio in 2016, and continuing to decline thereafter.
再看我們的美國神經科與其他(US Neuro and Other)產品組合,該組合主要由多年來收購而來的既有(legacy)產品構成,在此期間我們年初至今的數量下滑為7%。以淨價格(net price)基礎計算,我們實現了30%。需要注意的是,該產品組合中有61%在市場上有學名藥替代品,為醫師與病患提供較低成本的替代選擇。展望未來,該產品組合將在我們美國業務中占比愈來愈小。我們預期2016年其將約占產品組合的10%,並在此後持續下降。
As I mentioned before, there have been several research reports that contribute to the overall misinformation about our pricing. While these reports represent the individual's own opinions, when incorrect numbers begin to be quoted widely by others in the media, we feel compelled to correct this misinformation. A recent report from Deutsche Bank looked at the products that were over $10 million in sales. It reported that we raised price on 56 of our 69 products, representing 81% of our portfolio. It further suggested that we took, on average, a price increase of 66% on each of these products.
如我先前提到的,已有數份研究報告助長了外界對我們定價的整體錯誤資訊。雖然這些報告代表個人的觀點,但當不正確的數字開始被媒體中其他人廣泛引用時,我們覺得有必要更正這些錯誤資訊。德意志銀行近期的一份報告檢視了銷售額超過 1,000 萬美元的產品。該報告指出,我們在 69 項產品中的 56 項調漲價格,約占我們產品組合的 81%。報告並進一步暗示,我們在這些產品上平均每項調漲 66%。
In reality, we increased price on 85 of our 156 branded pharmaceutical products, or 54% of our products. And our average gross price increase was 36%. It is important to note that our realized price increase was 24%.
事實上,我們在 156 項品牌處方藥產品中的 85 項調漲價格,亦即 54% 的產品。而我們的平均名目(gross)漲價幅度為 36%。需要特別指出的是,我們的實現(realized)漲價幅度為 24%。
While we have listened to our shareholders to provide more price-volume disclosure, we also took a look at what other companies provide. When looking at the top 15 pharma companies, only four provide quantitative disclosure on their full portfolio. Historically, Valeant has provided qualitative disclosure on its full portfolio. Going forward, we will provide quantitative price-volume disclosure on our full portfolio. Specifically, we're committing to provide the chart on slide 20 and the chart on slide 21 every quarter. We believe this disclosure should address your concerns.
雖然我們已聽取股東意見,提供更多價格—銷量(price-volume)揭露,我們也檢視了其他公司提供的資訊。在前 15 大製藥公司中,只有 4 家對其完整產品組合提供量化揭露。過去,Valeant 對其完整產品組合提供的是質化揭露。未來,我們將對完整產品組合提供量化的價格—銷量揭露。具體而言,我們承諾每季提供第 20 頁投影片的圖表以及第 21 頁投影片的圖表。我們相信這項揭露應可回應各位的疑慮。
More important than the look-back is the influence of price as we move forward. As I mentioned in the memo a few weeks back, price flexibility is very limited outside the US. In the US, our business units, such as contact lenses, surgical, consumer, Solta and Obagi, also have limited price flexibility. In the pharmaceutical portfolio, we assume low single-digit price increases looking into 2016 and beyond. Furthermore, our mix is evolving, so the US Neuro and Other portfolio will only represent approximately 10% of our sales, and our US branded pharmaceuticals will represent approximately 40% of our total sales.
比起回顧更重要的是,展望未來時價格的影響。如我在幾週前的備忘錄中提到,美國以外地區的價格彈性非常有限。在美國,我們的事業單位,例如隱形眼鏡、外科、消費品、Solta 與 Obagi,也同樣只有有限的價格彈性。在處方藥產品組合方面,我們假設 2016 年及其後的價格調漲為低個位數百分比。此外,我們的產品組合正在演變,因此美國神經科與其他(US Neuro and Other)產品組合將僅約占我們銷售額的 10%,而我們的美國品牌處方藥將約占總銷售額的 40%。
Turning to our approach to US drug distribution, I want to clearly state that all of Valeant's drugs are available to all patients. Most of our US pharmaceutical products are available through the big three distributors. Our distribution is not designed to restrict access to our products.
談到我們在美國藥品配送的作法,我想清楚說明:Valeant 的所有藥品對所有病患皆可取得。我們在美國的大多數處方藥產品可透過三大經銷商取得。我們的配送設計並非為了限制取得我們的產品。
Turning to: How does Valeant work with specialty pharmacies, especially Philidor? The topic of specialty pharmacies has not been a focus of ours on past calls because we believe this was a competitive advantage that we did not want to disclose to our competitors. But given all the incorrect assertions by some, we will provide an update on this call.
接下來談:Valeant 如何與專科藥局合作,特別是 Philidor?過去的電話會議中,我們並未將專科藥局作為重點,因為我們認為這是一項競爭優勢,不希望對競爭對手揭露。但鑑於部分人士提出許多不正確的主張,我們將在本次電話會議中提供最新說明。
Similar to many pharmaceutical companies in the US, an increasing percentage of our revenue is coming from products dispensed through multiple specialty pharmacies. We find specialty pharmacies improve patients' access to medicines at an affordable price, and help ensure physicians are able to prescribe the medications they believe most appropriate for their patients. In almost all cases, our inventory with specialty pharmacies in this channel and the title to our medicine only transfers to the pharmacy when the actual prescription is filled. We find this significantly reduces our distribution fees and product returns.
與美國許多製藥公司類似,我們愈來愈高比例的營收來自於透過多家專科藥局配藥的產品。我們發現專科藥局能以可負擔的價格改善病患取得藥品的可近性,並協助確保醫師能為病患開立其認為最合適的藥物。在幾乎所有情況下,我們在此通路的專科藥局庫存,以及藥品所有權(title),僅在實際處方被配藥完成時才移轉至藥局。我們發現這能顯著降低我們的配送費用與產品退貨。
Currently, only [$15] million of inventory at WAC, or gross price, sits in our US specialty pharmacy channel. This is a small fraction, less than 5%, of our total in-channel inventory. The largest component of this specialty inventory is [Arestin].
目前,在我們美國專科藥局通路中,以 WAC(批發取得成本)或名目價格(gross price)計算的庫存僅有 [15] 百萬美元。這只占我們通路內總庫存的一小部分,不到 5%。此專科庫存中最大的一項是 [Arestin]。
Philidor, one of our specialty pharmacy partners, provides prescription services to patients across the country, and provides administrative services for our copay cards and is a dispensary that fills prescriptions. We have a contractual relationship with Philidor, and late last year we purchased an option to acquire Philidor if we so choose. Given accounting rules, we consolidate Philidor's financials. Inventory held at Philidor remains on Valeant's books, and is not included in the specialty pharmacy channel inventory.
Philidor 是我們的專科藥局合作夥伴之一,為全國病患提供處方服務,並為我們的自付額(copay)卡提供行政服務,同時也是負責配藥的藥局。我們與 Philidor 之間有合約關係,並於去年底購買了一項選擇權,讓我們可在需要時選擇收購 Philidor。依據會計準則,我們將 Philidor 的財務報表納入合併。Philidor 持有的庫存仍列在 Valeant 的帳上,且不包含在專科藥局通路庫存之內。
For many of our dermatology products, Philidor and other specialty pharmacies dispense our medicines before adjudication of the reimbursement is finalized to ensure patients get the medicines prescribed quickly. As a result, we take on the risk for non-reimbursement. We understand that Philidor provides services under our programs for commercially insured and cash paying claims only. Any claim that would be reimbursed in whole or in part by government insurance is not eligible for our copay subsidy programs. It does not restrict prescriptions it fills to any particular manufacturer. It dispenses generic products as specified in the patient's prescription or as requested by the patient.
對於我們許多皮膚科產品,Philidor 與其他專科藥局會在理賠核定(adjudication)完成前先行配藥,以確保病患能迅速取得處方藥品。因此,我們承擔未獲給付(non-reimbursement)的風險。我們了解 Philidor 僅在我們的計畫下,為商業保險與自費(cash paying)的理賠提供服務。任何將由政府保險全部或部分給付的理賠,均不符合我們自付額補助計畫的資格。其配藥並不限制於任何特定製造商的處方。其會依病患處方所指定,或依病患要求,提供學名藥(generic)產品。
Any non-Valeant prescriptions dispensed by Philidor are recorded as other revenue in our income statement, not product sales, and are, therefore, excluded from our organic growth calculations. The revenue for non-Valeant products is approximately $1 million per quarter. Since we do not recognize the revenue of our products until the prescriptions are filled, this consolidation has the impact of delaying revenue recognition as compared to products that are sold through traditional distribution channels.
Philidor 所配發的任何非 Valeant 處方,會在我們損益表中列為其他收入,而非產品銷售,因此不納入我們的有機成長(organic growth)計算。非 Valeant 產品的收入約為每季 100 萬美元。由於我們在處方完成配藥前不認列產品收入,與透過傳統配送通路銷售的產品相比,這種合併處理的影響是延後收入認列。
Next question: Why did Valeant's General Counsel send a letter to R&O? R&O is one of the specialty pharmacies in our network, and Valeant has shipped approximately $69 million at wholesale prices to them. This represents approximately $25 million at net prices. Any products R&O dispensed to patients were recognized as our revenues, and are reflected in our receivables. Any products still held by R&O are reflected in our inventory. R&O is currently improperly holding significant amounts it receives from payers. We will refrain from comment on active litigation, and look forward to showing in court that we are owed the money.
下一個問題:為何 Valeant 的總法律顧問(General Counsel)要致函 R&O?R&O 是我們網絡中的專科藥局之一,Valeant 已以批發價格向其出貨約 6,900 萬美元。以淨價(net prices)計算約為 2,500 萬美元。R&O 向病患配發的任何產品均已認列為我們的收入,並反映於我們的應收帳款中。R&O 仍持有的任何產品則反映於我們的存貨中。R&O 目前不當扣留其自付款方(payers)收取的大量款項。我們將避免評論進行中的訴訟,並期待在法庭上證明對方欠我們款項。
Valeant's patient assistant programs are administered by a reputable third party, and we fund outside foundations that have multiple donors. Eligibility is determined by the independent foundations. It is also important to note that eligibility for our in-house commercial access programs is limited to patients not covered by government programs. Looking at history, our commitment to patient assistant programs has grown at an annual compound rate of 128% from $53 million in 2012 to approximately $1 billion we expect to spend in 2016.
Valeant 的病患協助計畫由信譽良好的第三方管理,我們也資助具有多位捐助者的外部基金會。資格由獨立基金會決定。同樣重要的是,我們內部的商業可近性計畫(commercial access programs)之資格僅限於未受政府計畫涵蓋的病患。回顧歷史,我們對病患協助計畫的投入自 2012 年的 5,300 萬美元起,以 128% 的年複合成長率成長,至 2016 年我們預期支出約 10 億美元。
Recent government inquiries: As you all know, Valeant has responded to Senator McCaskill, and addressed her questions regarding Nitropress and Isuprel. In a letter to her last Wednesday, we discussed the history of Nitropress and Isuprel, the reimbursement process for hospital procedures involving Nitropress and Isuprel, the analysis and reasons underlying Valeant's pricing decision, and Valeant's programs designed to improve patient access, among other topics. We also noted that we are beginning an outreach to hospitals where the impact of a price change was significantly greater than average.
近期政府詢問:如各位所知,Valeant 已回覆 McCaskill 參議員,並回應她對 Nitropress 與 Isuprel 的相關問題。在上週三致她的信函中,我們討論了 Nitropress 與 Isuprel 的歷史、涉及 Nitropress 與 Isuprel 的醫院處置之給付流程、支撐 Valeant 定價決策的分析與原因,以及 Valeant 為改善病患可近性所設計的計畫等議題。我們也指出,我們正開始對那些因價格變動而受到顯著高於平均影響的醫院進行外展聯繫。
The Company recently received a subpoena from the US Attorney's Office for the District of Massachusetts, and a subpoena from the US Attorney's Office for the Southern District of New York. Our counsel is already in touch with the government, and the Company intends to cooperate with the investigations. We will not be answering questions or providing more information that was already covered in the press release on these matters.
本公司近期收到美國麻薩諸塞州聯邦檢察官辦公室的傳票,以及美國紐約南區聯邦檢察官辦公室的傳票。我們的法律顧問已與政府單位聯繫,公司擬配合相關調查。對於這些事項,我們將不會回答問題或提供任何超出新聞稿已涵蓋內容的進一步資訊。
Our approach to compliance and legal: Like other critical areas, we take both compliance and legal compliance seriously. For the past five years, we have been under a corporate integrity agreement started under legacy Biovail, and this CIA was just recently concluded. The CIA required extensive written policies and systems, significant training, a well-functioning compliance committee, and an annual audit by an independent organization. We were also required to file annual reports with the OIG. Our final report was filed in early 2015.
我們對合規與法務的做法:如同其他關鍵領域,我們嚴肅看待合規以及法律遵循。過去五年,我們一直受一項在 Biovail 歷史架構下啟動的企業誠信協議(CIA)約束,而該 CIA 近期已結束。該 CIA 要求建立廣泛的書面政策與制度、進行大量訓練、設置運作良好的合規委員會,並由獨立機構每年進行稽核。我們亦被要求每年向 OIG 提交年度報告。我們的最終報告已於 2015 年初提交。
In connection with Bausch + Lomb, we assumed compliance commitments made to the DOJ that includes maintaining an effective compliance program and annual certifications. In this industry, we must and we do take the matter of compliance very seriously.
就 Bausch + Lomb 而言,我們承接了先前對美國司法部(DOJ)所作的合規承諾,包括維持有效的合規計畫以及每年出具認證。在本產業中,我們必須、也確實非常嚴肅地看待合規議題。
With that, I will open up the call to questions.
接下來,我將開放電話會議進入提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
Your first question comes from the line of Shibani Malhotra from Nomura Securities International. Your line is now open.
第一個問題來自野村證券國際(Nomura Securities International)的 Shibani Malhotra。您的線路已開通。
- Analyst
- Analyst
Hi. Thank you for taking my question. My question is on R&D, Mike. You said that R&D is going to become more of a focus for Valeant going forward. Could you expand on that? How are you thinking of internal R&D versus your previous assertions that it's more efficient to license or buy in smaller companies or products? Thank you.
您好。謝謝讓我提問。Mike,我的問題是關於研發(R&D)。您提到未來研發將成為 Valeant 更重要的重點。能否進一步說明?您如何看待內部研發,相較於您先前所說授權引進或收購較小公司或產品更有效率的主張?謝謝。
- Chairman and CEO
- Chairman and CEO
Let me start and then I'm going to turn it over to Ari who leads our R&D efforts. I think what we've been able to show, at least to ourselves, is that our variable cost approach to R&D -- i.e., avoiding all the big fixed costs -- has been hugely productive. We've had a large return on our investment in dermatology, more recently in contact lenses and in surgical.
我先回答,然後把問題交給負責我們研發工作的 Ari。我認為我們至少已向自己證明,我們採取的研發變動成本模式——也就是避免所有龐大的固定成本——成效非常顯著。我們在皮膚科領域、以及較近期在隱形眼鏡與手術領域的投資,都獲得了很高的報酬。
So, we do think there's a path forward where we can earn a very good return. But how we spend the money will be different than the approach of most large pharmaceutical companies. Ari, maybe we can talk a little bit about some of the programs and what we're doing.
因此,我們確實認為有一條可行的前進道路,能夠取得非常好的報酬。但我們花錢的方式會不同於多數大型製藥公司。Ari,也許你可以談談一些專案以及我們正在做的事情。
- Company Group Chairman
- Company Group Chairman
The fundamental approach to R&D hasn't changed in terms of our controlling the critical points in R&D. For example, trial design and so on. We continue to believe that a lot of innovation occurs outside of large pharma in small institutions, academic start-ups, physician practices. We'll continue to source programs from there.
在研發的基本方法上並沒有改變,重點仍在於我們掌控研發中的關鍵環節。例如試驗設計等等。我們仍然相信,許多創新發生在大型藥廠之外,例如小型機構、學術新創、醫師診所。我們將持續從這些來源導入專案。
But as Mike said, we, through several years of dermatology [and dom], believe we have the capability needed to successfully launch products. And our pipeline of Phase 2 and 3 products in dermatology is [thinning]. Those obviously will attract funding and will continue to create opportunities like IDB-118, some of our normal acne compounds, other compounds in psoriasis, and in the future atopic dermatitis.
但如 Mike 所說,我們透過數年的皮膚科(以及 dom)經驗,相信我們具備成功上市產品所需的能力。而我們在皮膚科的第二期與第三期產品管線正在[變薄]。這些顯然會吸引資金,並將持續創造機會,例如 IDB-118、我們一些常規的痤瘡(青春痘)化合物、其他乾癬化合物,以及未來的異位性皮膚炎。
Eye care we've now had for two years and we're developing greater competency in the area. Mike alluded earlier to programs that are expanding in contact lens, in surgical, and consumer parts of eye care. And as we build the competencies in house, we understand the programs, the risk-reward profile and we'll continue to fund those.
眼科護理業務我們現在已經經營兩年,並正在該領域建立更高的能力。Mike 先前提到一些正在擴展的專案,涵蓋隱形眼鏡、手術,以及眼科護理的消費者端。隨著我們在內部建立能力、理解各項專案及其風險報酬特性,我們將持續為其提供資金。
Over time, we expect to develop similar competencies in GI, potentially in areas of oncology. So, we'll continue to be very prudent with investment, but what we're saying is we're better able now to chart the risk return of late-stage derisked assets.
隨著時間推進,我們預期在腸胃科(GI)以及可能在某些腫瘤領域建立類似的能力。因此,我們會持續非常審慎地投資;但我們要表達的是,我們現在更能夠評估後期、已降低風險資產的風險報酬。
- Analyst
- Analyst
Okay. How should we think about it from a financial perspective? And if you can't answer I'll just step out of the queue.
好的。從財務角度我們應該如何看待?如果你不能回答,我就先退出排隊。
- Chairman and CEO
- Chairman and CEO
Sure. R&D exceeded $100 million for the first time, at least since I've been here, in the quarter. We haven't put together a full 2016 budget but it's probably going to be between [$400] and [$500], is my guess, for next year.
當然。本季研發支出首次超過 1 億美元,至少自我在這裡以來是第一次。我們尚未完成 2016 年的完整預算,但我猜明年大概會在 [4] 億到 [5] 億之間。
- CFO
- CFO
$400 million and $500 million.
4 億美元到 5 億美元。
- Analyst
- Analyst
Yes -- million dollars. (laughter) $400, $500, that would be really good.
是的——百萬美元。(笑聲)4 百、5 百,那就真的太好了。
Operator
Operator
Your next question comes from Gregg Gilbert from Deutsche Bank. Your line is now open.
下一個問題來自德意志銀行(Deutsche Bank)的 Gregg Gilbert。您的線路已開通。
- Analyst
- Analyst
Yes, thanks. My question is not surprisingly about pricing. I wanted to ask you about this new disclosure you made today that you see a new pricing environment going forward. Can you talk about what's behind that? And how does that specifically affect how you model 2016? For example, you're talking about the EBITDA floor still being something you're very confident in. Is that because you're now all of a sudden more confident in volume growth or other factors? Can you talk to that point with some specificity? Thanks.
是的,謝謝。我的問題不意外是關於定價。我想問一下,您今天新增揭露提到,您預期未來將面臨新的定價環境。能談談背後原因嗎?以及這會如何具體影響你們對 2016 年的建模?例如,你們仍然非常有信心 EBITDA 的下限。這是因為你們突然對銷量成長或其他因素更有信心嗎?能否更具體地說明?謝謝。
- Chairman and CEO
- Chairman and CEO
Sure. You just have to read the newspapers. I think it's clear that the pharmaceutical industry is being aggressively attacked for past pricing actions. And that's not just Valeant, but I think it's all companies. I do think given that environment, the pricing that pharmaceutical companies will take in the future will be more modest, and we built that into our forecast for next year.
當然。你只要看看報紙就知道。我認為很明顯,製藥產業正因過去的定價行為而遭到強力抨擊。而這不只是 Valeant,我認為是所有公司都一樣。我確實認為在那樣的環境下,製藥公司未來的漲價幅度會更溫和,我們已把這點納入明年的預測。
I think we assume no more than 10% realized price for any of our products. But when we made that change to our 2016, but, as Rob pointed out, and then add the new businesses we're in and the outperformance from a growth standpoint, that's what makes us very comfortable with the 2016, all four being the $7.5 billion EBITDA. Those are our base assumptions in our plans for 2016 and we will provide specific guidance earlier in January of next year.
我想我們假設任何產品的實現價格(realized price)漲幅不會超過 10%。但當我們對 2016 年做出那項調整時,如 Rob 所指出的,再加上我們進入的新業務以及在成長面向的超預期表現,這些讓我們對 2016 年、四個季度合計達到 75 億美元 EBITDA 感到非常有把握。這些是我們 2016 年計畫中的基本假設,我們將在明年一月較早時提供具體指引。
Operator
Operator
Your next question comes from Tim Chiang from BTIG. Your line is now open.
下一個問題來自 BTIG 的 Tim Chiang。您的線路已開通。
- Analyst
- Analyst
Hi. Thanks. Mike, I know you talked about deleveraging. Could you provide a little bit more granularity in terms of how much debt you plan to pay down in 2016? Certainly you generate a lot of cash flow.
您好。謝謝。Mike,我知道你談到去槓桿。你能否更細緻地說明 2016 年計畫償還多少債務?你們確實產生大量現金流。
- Chairman and CEO
- Chairman and CEO
Sure. We have mandatory drawdown of about $560 million.
當然。我們有約 5.60 億美元的強制性償還(drawdown)。
- CFO
- CFO
$562 million.
5.62 億美元。
- Chairman and CEO
- Chairman and CEO
$562 million. So obviously we'll pay that next year. But we've also made a commitment -- we raised the debt during the Salix transaction -- we made a commitment to our bond holders and our bank on our bank debt that we would go beyond the mandatory. We haven't precisely come up with the exact number but we have a number of notes that are now callable. We will generate a lot of cash next year, so I suspect that the first half of next year we will make more than the mandatory reductions in debt.
5.62億美元。所以很明顯我們明年會支付那筆款項。但我們也做出了承諾——我們在Salix交易期間舉債——我們向債券持有人以及我們的銀行(就銀行借款)承諾,我們會超出強制性要求。我們尚未精確算出確切金額,但我們目前有一些票據已可提前贖回。我們明年將產生大量現金,因此我推測明年上半年我們會進行超過強制性要求的減債。
- Analyst
- Analyst
And, Mike, just one follow-up. You mentioned that you're considering selling the legacy business at the Company. Any thoughts on the timing of such a sale?
另外,Mike,再追問一個問題。你提到你們正在考慮出售公司旗下的傳統業務。對於這類出售的時點有什麼想法嗎?
- Chairman and CEO
- Chairman and CEO
We've been debating with our Board for the last few years. It's always been a plan of ours to increase the quality of the assets that we own. And I think the first major shift was when we bought B+ L which is a truly durable, great business that is doing really well for us.
過去幾年我們一直和董事會討論這件事。提升我們所持有資產的品質一直是我們的計畫。我認為第一個重大轉變是在我們收購B+L的時候,那是一門真正具韌性、非常優質的業務,對我們而言表現非常好。
And then with Salix, another set of products that are quite durable and with a lot of organic growth. So, we've been debating but I think given, again, everything that's happening, everything that's happened, what's happened to our multiple, I think that there's a reasonable chance that something happens over the next 12 months or so.
接著是Salix,這又是一組相當具韌性且具有大量內生成長的產品。因此我們一直在討論,但我認為考量到——再次強調——正在發生的一切、已經發生的一切,以及我們估值倍數的變化,我認為在未來大約12個月內發生某些事情的可能性相當合理。
- Analyst
- Analyst
And maybe just one last question -- you did mention stock buybacks. Are you in a position to do that today or in the near future?
也許最後一個問題——你確實提到股票回購。你們今天或在不久的將來有條件進行回購嗎?
- Chairman and CEO
- Chairman and CEO
We're in closed window today. But we will have to take a look at our cash. Again, we made a commitment to reduce our debt and it obviously depends on where our share price is. But I think that statement was as we think through the rest of this year in 2016, in view of this, that's the time frame.
我們目前處於封閉期。但我們必須檢視我們的現金狀況。再次強調,我們承諾要降低負債,而這顯然也取決於我們的股價水準。但那句話的意思是:當我們思考今年剩餘時間以及2016年、並將此納入考量時,那就是我們所指的時間範圍。
Operator
Operator
Your next question comes from Lois Chen from Guggenheim. Your line is now open.
下一個問題來自Guggenheim的Lois Chen。您的線路已開通。
- Analyst
- Analyst
Thanks for taking my question. My question here is, if you don't have the benefit of price increases, can you still meet or beat your 2016 EBITDA guidance? I know you addressed some of this earlier. And then, secondly, just on the 80% gross margin forecast, how much of that is based on price increase, how much of that is manufacturing efficiency, scale and volume gains? Thank you.
謝謝讓我提問。我的問題是,如果沒有漲價帶來的助益,你們仍能達成或超越2016年的EBITDA指引嗎?我知道你先前已經回應過其中一部分。第二個問題是,關於80%毛利率的預測,其中有多少是基於漲價,有多少是來自製造效率、規模與銷量提升?謝謝。
- Chairman and CEO
- Chairman and CEO
Our reduction in COGS has to do with efficiencies and mix, not on price. So efficiencies, primarily in the contact lens where we're just gearing up ULTRA, and then BioTrue volumes continue to go up significantly, that the yields are improving. The guys in manufacturing are just doing a great job there.
我們的銷貨成本(COGS)下降與效率與產品組合有關,與價格無關。因此是效率,主要在隱形眼鏡方面,我們正在加速推進ULTRA;另外BioTrue的銷量持續大幅上升,使得良率在改善。製造端的同仁在那裡做得非常出色。
From a mix standpoint, Salix is becoming a larger piece of our portfolio every quarter. And the COGS there are lower than in the legacy business and we'll continue to see the impact there. What's really going to dramatically, on a going forward basis, improve our COGS will be the fact that Xenazine's gone generic.
從產品組合的角度來看,Salix每一季都在我們的產品組合中占比更大。而那邊的銷貨成本低於傳統業務,我們會持續看到其影響。真正會在未來顯著改善我們銷貨成本的,是Xenazine已經進入學名藥競爭。
- CFO
- CFO
Correct.
沒錯。
- Chairman and CEO
- Chairman and CEO
And I think we were only realizing, because of the agreement with our partner, Lundbeck, we were only realizing like 50% gross margins. In terms of our EBITDA for 2016, I think we're only going to say today that we feel very comfortable with the $7.5 billion and we expect our guidance next year will exceed that.
而且我認為,由於與合作夥伴Lundbeck的協議,我們實際上只能實現大約50%的毛利率。至於我們2016年的EBITDA,我想我們今天只能說,我們對75億美元非常有信心,而且我們預期明年的指引會高於這個數字。
Operator
Operator
(Operator Instructions)
(接線員指示)
Your next question comes from the line of Alex Arfaei from BMO Capital Markets.
下一個問題來自BMO Capital Markets的Alex Arfaei。
- Analyst
- Analyst
A question on the Salix revenue -- you recognized $460 million versus guidance of $300 million. How much of that difference was discretionary revenue recognition? Or does it reflect changes in demand since you provided that guidance?
關於Salix營收的問題——你們認列了4.60億美元,而指引是3.00億美元。其中差異有多少是可裁量的營收認列?或者這反映了自你們提供該指引以來需求的變化?
And, also, could you update us on the status of expected cost synergies from Salix? Thank you.
另外,你們能否更新一下Salix預期成本綜效的進度?謝謝。
- Chairman and CEO
- Chairman and CEO
Could you explain what you mean by discretionary revenue?
你能解釋一下你所說的「可裁量的營收」是什麼意思嗎?
- Analyst
- Analyst
Sure. Just trying to figure out -- you said it was going to be about $300 million, you're recognizing $460 million. So, I'm just trying to figure out what changed since you provided that guidance.
當然。我只是想釐清——你們說大約會是3.00億美元,但你們認列了4.60億美元。所以我想了解,自你們提供該指引以來,有什麼改變。
- Chairman and CEO
- Chairman and CEO
I think a couple things. One is we don't know exactly -- we know what the inventory is with the big three, we don't know how much inventory there is in some of the other distributors because there were no agreements in place to tell us that. What we're not doing is providing any discounts or any incentives for people to buy Salix products.
我想有幾個因素。第一,我們不完全清楚——我們知道三大通路商的庫存水位,但我們不知道其他一些經銷商有多少庫存,因為當時沒有協議要求他們告知我們。我們沒有做的是:不提供任何折扣或任何誘因來讓大家購買Salix產品。
Also, the inventory was not sort of -- it wasn't that everyone had like five months of extra inventory of everything. It really varied by product. So, there might have been a year's worth of one product and four months of another product. That's why it's taking time. It's taking time to reduce those inventories.
另外,庫存並不是那種——並不是每個人所有產品都多了五個月的額外庫存。它其實因產品而異。所以,某個產品可能有一年的庫存,另一個產品可能只有四個月。這就是為什麼需要時間。需要時間來降低那些庫存水位。
But I think the sales, the fact that sales have increased -- again, there's no sales incentive, I think it's all growth. The products continue to grow above what we had forecasted in our deal model. And, as Rob mentioned, we're going to continue to try to be conservative. We don't want to get ahead of ourselves.
但我認為銷售額之所以增加——再次強調,沒有銷售激勵——我認為完全是成長所致。這些產品的成長持續高於我們在交易模型中的預測。而且如Rob所提,我們會持續努力保持保守。我們不想操之過急。
Then integration costs, the integration costs we've exceeded --.
至於整合成本,整合成本我們已經超過——。
- CFO
- CFO
$550 million was the original target. We've exceeded it. I think we reported that in the last quarter.
原先目標是5.50億美元。我們已經超過了。我想我們在上一季已經報告過。
Just one other thing on the inventory, and we mentioned this on the last call, again, we know factually and in detail what's at the big three. We don't know what was out there. I think as we got under it we found out there was more out there and more wholesalers and were, frankly, just being conservative.
關於庫存還有一點,且我們在上次電話會議也提過:同樣地,我們對三大通路商那邊的庫存有事實依據且掌握得很細。我們不知道外面還有多少。我想當我們深入了解後,發現外面還有更多庫存、也有更多批發商,而我們坦白說只是採取保守作法。
Operator
Operator
Your next question comes from Marc Goodman from UBS. Your line is now open.
下一個問題來自UBS的Marc Goodman。您的線路已開通。
- Analyst
- Analyst
Mike, I'm curious about this in-licensing of brodalumab. This is a different type of R&D risk than you've done before. Why are you doing this deal? Will there be more deals like it?
Mike,我對這次引進授權(in-licensing)的brodalumab感到好奇。這是一種不同於你們以往所承擔的研發風險類型。你們為什麼要做這筆交易?未來還會有更多類似的交易嗎?
And then if you're going to divest neuro and those types of products, in the past you've bought these types of products that have high NPV but obviously are anchors to the growth of the Company, but obviously create a lot of value. You described it as -- if we were a private company wouldn't you want me to do this because this is adding a lot of value. So, if you're divesting this portfolio, does that mean you are no longer going to pursue that type of strategy? Thanks.
另外,如果你們要剝離神經科以及這類產品,過去你們買過這類NPV很高、但顯然會拖累公司成長、然而也能創造大量價值的產品。你曾把它描述為——如果我們是一家私人公司,你不會希望我這麼做嗎?因為這能增加很多價值。所以,如果你們要剝離這個產品組合,是否意味著你們不再追求那種策略?謝謝。
- Chairman and CEO
- Chairman and CEO
Let me answer the second one first and then I'll have Ari talk about broda. We didn't say we'd sell it. We said we would sell it or spin it off. If we spin it off then shareholders would have the opportunity to remain shareholders of that type of Company that certainly could create value over time. But given the current environment, I think that probably doesn't make sense for us to hold onto it, especially given what's happened to our multiple with everything there in the press. So, hopefully we'll figure out a way to do it. The shareholders could continue to participate in an entity that is maybe not a growth co, but could be a big dividend co. Ari?
我先回答第二個問題,然後再請 Ari 談談 broda。我們並沒有說我們會把它賣掉。我們說的是,我們會賣掉它或將其分拆。如果我們分拆,股東將有機會繼續成為那類公司的股東,長期來看這當然可能創造價值。但就目前的環境而言,我認為我們大概不適合繼續持有它,尤其考量到媒體報導對我們估值倍數造成的影響。所以,希望我們能找到一個方式來處理它。股東可以繼續參與一個也許不是成長型公司、但可能是高股利型公司的實體。Ari?
- Analyst
- Analyst
Hold on one second. Does that mean you wouldn't do a Targretin type of product anymore?
等一下。那是否表示你們之後不會再做 Targretin 類型的產品了?
- Chairman and CEO
- Chairman and CEO
As we mentioned, it's unlikely. It's unlikely we would do a Targretin type deal in the foreseeable future.
如同我們提到的,可能性不高。在可預見的未來,我們不太可能做 Targretin 類型的交易。
- Analyst
- Analyst
Okay.
好的。
- Company Group Chairman
- Company Group Chairman
On your question of brodalumab, I think this is emblematic of Valeant's mission. First of all, moderate to severe psoriasis is a debilitating disease. It's an area of significant unmet need and, consistent with our mission, we are focused on this area. We have IDP-118. We understand the condition, the disease, and the debilitating illness.
關於你對 brodalumab 的問題,我認為這正體現了 Valeant 的使命。首先,中重度乾癬是一種使人衰弱的疾病。這個領域存在顯著的未被滿足需求,且與我們的使命一致,我們專注於此領域。我們有 IDP-118。我們了解這個病況、這種疾病,以及這種會造成嚴重影響的病症。
Second, our focus on doctors. A big reason we went after this compound was that many of our physicians and KOLs recommended that we do this. They wanted Valeant to pick up this drug and bring it to the market for the sake of the many patients who will benefit. And we listened to our doctors and moved forward.
第二,我們聚焦於醫師。我們之所以追求這個化合物的一大原因,是因為許多醫師與 KOL 建議我們這麼做。他們希望 Valeant 接手這個藥物並將其推向市場,讓許多將受益的病患能夠使用。我們聽取了醫師的意見並推進此事。
Finally, we believe that this will generate good returns for shareholders. We're very comfortable with the safety and efficacy profile. We have a terrific team in R&D and in regulatory. We're going to be in discussions with the FDA. We expect to submit in November, as Mike had mentioned earlier. And we have a great team of dermatology marketers and salespeople and MSLs who we believe will do a terrific job in the market for our shareholders.
最後,我們相信這將為股東帶來良好回報。我們對其安全性與療效特徵非常有信心。我們在研發與法規方面有一支非常出色的團隊。我們將與 FDA 進行討論。如 Mike 先前提到的,我們預期在 11 月提交。我們也有一支優秀的皮膚科行銷與銷售團隊以及 MSL,我們相信他們將在市場上為股東做出卓越表現。
- Chairman and CEO
- Chairman and CEO
Marc, I just wanted to return to your question about the types of deals that we do. I would like to note that of the approximately 150 deals that we've done since I've gotten here, I can count on one hand the number of deals where we have acquired mispriced assets as part of the thesis of the deal. Next question.
Marc,我想回到你關於我們所做交易類型的問題。我想指出,自從我來到這裡以來,我們大約做了 150 筆交易,其中以「收購被錯誤定價的資產」作為交易論點之一的交易,我一隻手就數得出來。下一個問題。
Operator
Operator
Your next question comes from the line of Irina Koffler from Mizuho. Your line is now open.
下一個問題來自 Mizuho 的 Irina Koffler。您的線路已開通。
- Analyst
- Analyst
I wanted to see if through this pricing controversy if you've had any dialogue with the pharma lobby or any other industry groups, and whether or not there's been any feedback or direction that way. Thanks.
我想了解,在這次定價爭議期間,你們是否與製藥遊說團體或其他產業團體有任何對話?以及是否有收到任何回饋或指引?謝謝。
- Chairman and CEO
- Chairman and CEO
As we mentioned on the call, unfortunately we're not able to expand further on any dealings with the government.
如同我們在電話會議中提到的,很遺憾,我們無法就任何與政府往來的事項進一步說明。
Operator
Operator
Your next question comes from David Amsellem with Piper Jaffray. Your line is now open.
下一個問題來自 Piper Jaffray 的 David Amsellem。您的線路已開通。
- Analyst
- Analyst
Thanks. What's the level of confidence that you'll be able to find a taker for the neuro business, given the environment? And are you essentially conceding that that business is radioactive?
謝謝。在目前的環境下,你們有多大把握能為神經科業務找到接手方?你們是否等於承認那項業務已經「帶有毒性」、沒人敢碰?
And then in terms of R&D, do you have a sense going forward, or maybe give us a sense of R&D as a percentage of sales or how you're thinking about it in terms of either percentage basis or in absolute terms given that it looks like you're recalibrating your thinking as it relates to R&D. Thanks.
另外,就研發而言,往後你們是否有概念,或能否讓我們了解研發費用占營收的比例,或你們如何思考研發投入(以比例或絕對金額),因為看起來你們正在重新校準對研發的看法。謝謝。
- Chairman and CEO
- Chairman and CEO
David, I think the neuro and other has very good cash flows. Again, we can think of a spin, we can think of taking it private, or we could think of selling it. So, there's many ways of creating value. I think a number of our shareholders have already mentioned to me that they'd like to be part of, if we were ever to consider doing a sale like this, they'd like to have an ownership stake in this business on a going forward basis.
David,我認為神經科及其他業務的現金流非常好。同樣地,我們可以考慮分拆、考慮私有化,或考慮出售。因此,有很多創造價值的方式。我想我們的一些股東已經跟我提過,如果我們曾考慮進行這樣的出售,他們希望能在未來持續持有這項業務的股權。
But obviously if we can't come up with an approach that creates value for our current shareholders then we won't be able to dispose of it. It's too premature to think about our R&D spend as a percentage of sales, but it would certainly continue to be well below that of most of our competitors to do R&D in the traditional way. Because I think what we have proven to ourself is our non-traditional R&D approach is highly productive. We're getting very strong returns on investment. So, anywhere that we are earning that disproportionate return we are happy to pull in more capital, which is what we'll be doing. Next question.
但顯然,如果我們無法提出一個能為現有股東創造價值的方案,那我們就無法處置它。現在就把研發支出視為營收百分比來思考還太早,但若以傳統方式做研發,我們的研發占比肯定仍會遠低於多數競爭對手。因為我認為我們已向自己證明,我們的非傳統研發方法具有高度生產力。我們獲得非常強勁的投資報酬。因此,只要我們能賺取那種不成比例的回報,我們就樂於投入更多資本,而這也正是我們將要做的。下一個問題。
Operator
Operator
Your next question comes from the line of Lennox Gibbs from TD Securities. Your line is now open.
下一個問題來自 TD Securities 的 Lennox Gibbs。您的線路已開通。
- Analyst
- Analyst
Good morning. Thanks. The Senate subcommittee hearings that Howard Schiller presented to back in late July. What, if any, were your specific concerns coming out of those sessions? What were the key take-aways?
早安。謝謝。關於參議院小組委員會聽證會,Howard Schiller 在 7 月下旬曾出席作證。從那些會議中,你們具體有哪些疑慮(如果有的話)?主要的重點收穫是什麼?
- Chairman and CEO
- Chairman and CEO
Again, Lennox, I'm sorry, we just can't comment on anything that has to do with the government on this call.
Lennox,再次抱歉,我們在這通電話會議上無法評論任何與政府相關的事情。
- Analyst
- Analyst
Sorry. Are there --.
抱歉。是否有——。
- Head of IR
- Head of IR
I think we lost him. Next question.
我想我們跟他斷線了。下一個問題。
Operator
Operator
Your next question comes from Gary Nachman from Goldman Sachs. Your line is open.
下一個問題來自 Goldman Sachs 的 Gary Nachman。您的線路已開通。
- Analyst
- Analyst
Hi, Mike. Could you elaborate on what kind of pricing discussions you're having with some of the hospitals regarding Isuprel and Nitropress? Would you reconsider the current pricing for any of your other products, maybe taking it down, in certain cases? And the 15% pricing contribution in US branded, where did most of that come from, new versus legacy products? Thanks.
嗨,Mike。你能否更詳細說明,你們就 Isuprel 和 Nitropress 與部分醫院正在進行哪些定價討論?你們是否會在某些情況下重新考慮其他產品的現行定價,例如調降?另外,美國品牌藥 15% 的價格貢獻主要來自哪裡——新產品還是既有產品?謝謝。
- Chairman and CEO
- Chairman and CEO
Maybe in reverse -- most of the pricing came from the neuro and other, as we showed. We showed you the top derm products which represent a big portion of our sales. We showed you the top ophthalmology. So it's primarily, almost solely, from the neuro and other segment of our business.
也許倒過來回答——大部分的價格貢獻來自神經科及其他業務,如同我們所展示的。我們向各位展示了主要的皮膚科產品,它們占我們銷售額很大一部分。我們也展示了主要的眼科產品。因此,主要、幾乎完全,來自我們業務中的神經科及其他部門。
In terms of the hospitals, we reached out to a number of the hospitals. More is being done. And what we're discussing is right now we do not use GPOs. We just recently got into the hospital business. We don't use GPOs so we're talking about directly contracting with hospitals. And if we can do that we can avoid sending the products through distributors, which will save us money and we can pass along those savings. What we're going to try to do is see if we can't have individual contracts across all our products, which we think in the end could benefit us.
至於醫院方面,我們已主動聯繫多家醫院。目前還在做更多工作。我們討論的重點是:目前我們不使用 GPO。我們最近才進入醫院業務。我們不使用 GPO,因此我們在談的是與醫院直接簽約。如果能做到,我們就能避免產品經由經銷商流通,這會為我們節省成本,而我們也可以把這些節省讓利出去。我們將嘗試看看能否針對我們所有產品簽訂個別合約,我們認為最終這可能對我們有利。
And in terms of taking prices up and down, we always review our portfolio. We have taken price down this year on some products and price up. So we'll continue to do that as we move forward.
至於調升或調降價格方面,我們一向都會檢視我們的產品組合。今年我們已對部分產品降價,也對部分產品漲價。因此,未來我們也會持續這麼做。
Operator
Operator
Your next question comes from the line of David Risinger from Morgan Stanley. Your line is now open.
下一個問題來自摩根士丹利(Morgan Stanley)的 David Risinger。您的線路已開通。
- Analyst
- Analyst
Thanks very much. Mike, could you just restate or provide a little bit more detail on your 2016 outlook with respect to price, what your pricing expectations are for the US prescription drug business overall? And then I think you made a comment that you're not going to be raising price any more than 10%. I didn't know if that was for US Rx or global Rx, so any additional color you could provide would be great.
非常感謝。Mike,你能否重申或再多提供一些關於你們 2016 年展望中「價格」的細節,也就是你們對美國處方藥業務整體的定價預期?另外我想你提到過,你們不會把價格上調超過 10%。我不確定那是針對美國處方藥(US Rx)還是全球處方藥(global Rx),如果能再補充一些說明就太好了。
- Chairman and CEO
- Chairman and CEO
For our budget for 2016, I was answering a question about what assumptions we made that allowed us to reaffirm the $7.5 billion EBITDA. In that budget we did not assume more than a 10% realized price -- that's realized price -- on any of our products. So that's how we got to the budget.
就我們 2016 年的預算而言,我是在回答一個問題:我們做了哪些假設,讓我們能夠重申 75 億美元的 EBITDA。在那份預算中,我們並未假設任何產品的已實現價格(realized price)會超過 10%——這裡指的是已實現價格。因此,我們就是在這樣的假設下編製預算的。
We're not saying we're never going to take a price increase of more than 10% on our products. As you've seen, sometimes you need to take a little bit more in order to actually realize price increases. But certainly the pricing assumptions we made for next year on our most recent budget are lower than what we had in our previous budget.
我們並不是說我們永遠不會對產品進行超過 10% 的漲價。如你所見,有時候為了真正實現價格上調,你需要調得稍微多一些。但可以確定的是,我們在最新預算中對明年的定價假設,低於我們先前預算中的假設。
But we also have higher growth rates for some of our core businesses because of the performance we're seeing and the growth we're getting. And we also have a number of new businesses, like Sprout and Amoun. And we have a number of new product launches that we believe next year, Vesneo probably being the most significant but also some derm launches and Luminesse. So, there's a number of products which will also help on the growth side.
不過,由於我們看到的表現與取得的成長,我們部分核心業務的成長率也更高。此外,我們也有一些新業務,例如 Sprout 和 Amoun。我們也有多項新產品上市,我們相信明年會推出,其中 Vesneo 可能是最重要的一項,另外還有一些皮膚科(derm)產品上市以及 Luminesse。因此,有不少產品也將在成長面提供助力。
- Analyst
- Analyst
That's great. And then just separately, you discussed alternate fulfillment, could you just put that in perspective, maybe what percentage of the US brand Rx business alternate fulfillment is and how much of that is Philidor?
很好。另外,你們提到替代履約(alternate fulfillment),你能否幫我們放在脈絡中理解一下,例如在美國品牌處方藥(US brand Rx)業務中,替代履約大概占比多少,其中又有多少是 Philidor?
- Chairman and CEO
- Chairman and CEO
Sure. It's really primarily our dermatology brands and then some of our specialty products like Ruconest, Arestin, and some of the other orphan drugs. For certain products it's quite large. For Jublia it's probably 15%. For a lot of other dermatologies it's much less. I'm sorry, I can't -- it's significant but it's -- I don't know the precise number but it's certainly, of our US portfolio, 10%, 20%, maybe. Tanya's nodding probably closer to 10%.
當然。這主要是我們的皮膚科品牌,另外還有一些專科產品,例如 Ruconest、Arestin,以及其他一些罕見疾病用藥(orphan drugs)。對某些產品而言,占比相當大。以 Jublia 來說,可能約 15%。對許多其他皮膚科產品而言則低得多。抱歉,我無法——它很顯著,但——我沒有精確數字;不過就我們的美國產品組合而言,可能是 10%、20% 左右。Tanya 點頭,可能更接近 10%。
Operator
Operator
Your next question comes from Annabel Samimy from Stifel. Your line is now open.
下一個問題來自 Stifel 的 Annabel Samimy。您的線路已開通。
- Analyst
- Analyst
Hi. Thanks for taking my question. You had mentioned that rifaximin SSD program failed. Can you talk about, with R&D, where you're going to be continuing to focus the GI R&D, which programs are still ongoing? And how are you approaching GI R&D? Is it any different than what you're doing in derm or the other areas? Thanks.
嗨。謝謝讓我提問。你們提到 rifaximin 的 SSD 計畫失敗了。能否談談在研發(R&D)方面,你們接下來會把腸胃道(GI)研發重點放在哪裡,哪些計畫仍在進行中?以及你們如何推進 GI 研發?這和你們在皮膚科或其他領域所做的有什麼不同嗎?謝謝。
- Company Group Chairman
- Company Group Chairman
It's different because it's a recent acquisition and we don't want to get too far in front of our skis. So, rule number one is we take the programs, we see them through to completion, we see what we have and we inherit them. So, the SSD program failed. It doesn't mean we won't pursue a program like that we're looking with our R&D team. We're analyzing the signals, as Mike said earlier. We're going to see if there might be a possibility to create a program with different dosages.
這確實不同,因為那是近期收購而來的,我們不想操之過急。所以第一條原則是:我們把既有計畫一路做到完成,看看我們手上有什麼,並承接這些計畫。因此,SSD 計畫失敗了。但這不代表我們不會在研發團隊的評估下追求類似的計畫。正如 Mike 先前所說,我們正在分析相關訊號。我們會看看是否有可能透過不同劑量來建立一個計畫。
And as we continue to build our expertise in GI we'll find other programs. There are a couple of legacy studies programs that are continuing, such as the prophylaxis for [HE] and Ruconest and so on.
而且隨著我們持續建立在 GI 領域的專業能力,我們也會找到其他計畫。目前仍有幾個既有研究計畫在持續進行,例如針對 [HE] 的預防性治療,以及 Ruconest 等等。
Operator
Operator
Your next question comes from Chris Schott from JPMorgan. Your line is now open.
下一個問題來自摩根大通(JPMorgan)的 Chris Schott。您的線路已開通。
- Analyst
- Analyst
Great. Thanks for the question. Just had two here. Maybe just a bigger picture one on the broader M&A environment. Your business increasingly seems focused on durable growth. Could you talk about how large of an opportunity set and how competitive of an environment you're seeing for these type of assets? As we listen to these calls, it seems like many of your competitors are looking to make a similar pivot in their business towards more growth, towards more durable assets. I'm just trying to understand a little bit as you focus what that means.
很好。謝謝提問。我這裡有兩個問題。第一個可能是較宏觀的,關於整體併購(M&A)環境。你們的業務似乎越來越聚焦在可持續的成長。能否談談你們看到這類資產的機會集合有多大,以及競爭環境有多激烈?從這些電話會議聽起來,許多競爭對手也在尋求類似的轉向,把業務轉向更高成長、更加耐久的資產。我想更了解當你們聚焦於此時,這代表什麼。
The second question was on emerging market growth. It slowed in several regions. Has the longer-term outlook changed for these markets? I think you mentioned some efforts to reaccelerate growth. Can you maybe just elaborate a little more on that portion of it, specifically on the Latin American business and Russia, as well. Thanks so much.
第二個問題是關於新興市場成長。在若干地區成長放緩。這些市場的長期展望是否有所改變?我想你們提到了一些重新加速成長的努力。能否再多談一點這部分,特別是拉丁美洲業務以及俄羅斯?非常感謝。
- Chairman and CEO
- Chairman and CEO
Sure, Chris. In terms of competition we're seeing in the M&A area, quite honestly we're still not seeing much in the assets that we're pursuing. Now, you may have to remember that I do think our strategy, both in terms of the emerging market piece of it as well as we're in contact lenses, we're in surgical devices for ophthalmology, many of these companies I think you're alluding to aren't in those areas so they wouldn't be competing there.
當然,Chris。就我們在併購領域看到的競爭而言,坦白說,在我們正在追求的資產上,我們仍然沒有看到太多競爭。不過你可能要記得,我確實認為我們的策略——不論是新興市場那一塊,或是我們在隱形眼鏡、眼科手術器械等領域——你所暗示的許多公司並不在這些領域,因此不會在那裡與我們競爭。
Most of them I don't think are looking at derm Rx assets. So probably the area that would probably be most competitive would be ophthalmology Rx, and prices for those assets are quite high. So I'd says that's probably the area where it's going to be most difficult. And there's not a ton of pipeline available, unlike dermatology and GI.
我認為他們大多也不會去看皮膚科處方藥(derm Rx)資產。因此,可能競爭最激烈的領域會是眼科處方藥(ophthalmology Rx),而那些資產的價格相當高。所以我會說,那大概是最困難的領域。而且可供選擇的研發管線並不多,不像皮膚科和 GI 那樣。
In terms of the emerging markets, we're very pleased with Asia. Our team's doing an outstanding job there. I think Latin America, our team's doing great down there. Mexico, despite a tough market, they're doing extremely well.
至於新興市場方面,我們對亞洲非常滿意。我們的團隊在那裡做得非常出色。我認為在拉丁美洲,我們的團隊在那邊也做得很好。墨西哥儘管市場艱難,他們的表現仍然非常好。
We just got into Colombia which we think is a good market. Our team down in Argentina and Brazil are doing a good job. It's just a tough market. It's almost a very small business.
我們剛進入哥倫比亞,我們認為那是一個不錯的市場。我們在阿根廷和巴西的團隊也做得很好。只是那是一個艱難的市場。那幾乎是一個非常小的業務。
Where we've had our problems recently has been in Europe. That's where I was talking about we need to reaccelerate growth. We have a number of products across many of these countries, new products that we'll be introducing this year. In a sense, we've replenished our pipeline, which will help a lot.
我們最近遇到問題的地方是在歐洲。那就是我剛才提到我們需要讓成長重新加速的地方。我們在其中許多國家都有多項產品,今年也會推出一些新產品。某種程度上,我們已經補足了產品管線,這將帶來很大幫助。
This year we didn't have as many product launches, which is my fault. I think we weren't as focused on the pipeline as we should have been in Europe. And then also it's just a tough environment. We all know what's happening in Russia and the price of oil. Russia I think will come back strongly.
今年我們的產品上市沒有那麼多,這是我的責任。我認為我們在歐洲對產品管線的重視程度不如應有。另外,整體環境也確實艱難。大家都知道俄羅斯的情況以及油價的影響。我認為俄羅斯會強勁復甦。
I think with the closing of Amoun, we're a significant player in the Middle East where the market continues to grow quite nicely. And in Poland we made a switch in terms of our general manager. That's always been an important, strong market for us and our performance there has not been as strong recently so we made a change in management there which I think will help, as well. Next question.
我認為隨著 Amoun 交易完成,我們在中東已是重要的參與者,而該市場仍持續相當不錯地成長。另外在波蘭,我們在總經理人選上做了調整。那一直是我們重要且強勢的市場,但近期表現不如以往,因此我們更換了當地管理層,我認為這也會有所幫助。下一題。
Operator
Operator
Your next question comes from Andrew Finkelstein from Susquehanna. Your line is now open.
下一個問題來自 Susquehanna 的 Andrew Finkelstein。您的線路已開通。
- Analyst
- Analyst
Thanks very much for taking the question. You're talking a bit about the emerging markets and the business now is much more heavily weighted to the US than it has been in the past. So, as you look at business development in views of the type of durable assets you want as well as the focus you've always had on where disproportionate returns can be found, how do you think about what the balance of the business should look like as you look out over the medium term?
非常感謝讓我提問。您談到一些新興市場,而目前業務相較過去更偏重美國。因此,當您從業務發展角度、考量您想要的耐久型資產類型,以及您一向聚焦於可取得超額報酬的領域時,您如何看待中期來看業務應該呈現的平衡狀態?
- Chairman and CEO
- Chairman and CEO
It's an excellent point that emerging markets and ex-US has become a less large part of our business but it really hasn't been anything we've done. It's really been the US dollar. It's FX. It's the third year in a row that it's really -- so, all companies are, I think, seeing that piece of their business continues to shrink.
這點說得很好:新興市場與美國以外地區在我們業務中的占比變小了,但其實不是我們做了什麼造成的。主要是美元的因素。是外匯(FX)。這已經是連續第三年如此——我想所有公司都看到他們那部分業務持續縮小。
I think that if we thought that the US dollar would only continue to strengthen we would not put any capital to work outside of the US. But we don't believe that. It's just not sustainable for the world. So, we will continue to look both in the US and outside the US for opportunities.
我認為如果我們覺得美元只會持續走強,我們就不會把任何資本投入美國以外。但我們不這麼相信。這對全球而言並不可持續。因此,我們會持續在美國以及美國以外尋找機會。
There are some markets, and I mentioned earlier in the call, markets like Argentina and Brazil, where I think the outlook for their currencies is not great until they work through their issues. So, those are markets that we probably wouldn't deploy capital. Someone like the Middle East with the high growth rates, and if you look at the population or what demographics are going to do in terms of healthcare. I think if you look at the pricing of drugs, which I think in Egypt the average 30-pack is like $0.70, there I do think economics will over the long term work in our favor.
有些市場——我在電話會議前面也提到——例如阿根廷和巴西,我認為在它們解決自身問題之前,其貨幣前景不佳。所以那些市場我們可能不會部署資本。像中東這類高成長市場,若看人口結構或人口統計對醫療保健需求的影響。再看藥品定價,我記得在埃及平均一盒 30 顆裝大概是 0.70 美元;在那裡我確實認為長期而言經濟效益會對我們有利。
Operator
Operator
Your next question comes from the line of Douglas Tsao from Barclays. Your line is now open.
下一個問題來自 Barclays 的 Douglas Tsao。您的線路已開通。
- Analyst
- Analyst
Hi. Good morning. Thanks for taking the questions. Mike, when we step back and think about business development, how are you viewing the landscape today, especially given the dislocation that we've seen in the capital markets for a lot of spec pharma and biotech names? Has that increased your opportunity set or are things looking more attractive right now?
嗨。早安。謝謝讓我提問。Mike,當我們退一步思考業務發展時,您如何看待當前的環境,特別是考量到我們在資本市場看到許多投機型製藥與生技公司出現的錯位(dislocation)?這是否擴大了您的機會集合,或是現在看起來更具吸引力?
- Chairman and CEO
- Chairman and CEO
Certainly at lower prices, as long as the Company has good fundamentals, it certainly makes it more attractive. I think, on the other hand, we've been hit more than most, if not anyone, so actually using our equity is no longer an option at all for us. I think we will continue to look for cash deals.
當然,在價格較低時,只要公司基本面良好,確實會更具吸引力。但另一方面,我們受到的衝擊比大多數公司都大,甚至可能比任何公司都大,所以實際上用我們的股票作為對價對我們而言已完全不是選項。我認為我們會持續尋找以現金進行的交易。
But, again, I do want to re-emphasize that our commitment to reducing our leverage is first and foremost, so we will make sure we do get under four times. But that still leaves a lot of cash to either do deals or deploy. I don't think there's any acquisition right now that would earn the return of buying back Valeant shares. So, that will also be part of the consideration.
不過,我仍想再次強調:我們降低槓桿的承諾是首要任務,因此我們會確保把槓桿降到 4 倍以下。但即便如此,仍會留下大量現金可用於做交易或進行資本部署。我不認為目前有任何收購能帶來比回購 Valeant 股票更高的報酬。因此,這也會納入考量。
Operator
Operator
Your next question comes from Sumant Kulkarni of Bank of America-Merrill Lynch. Your line is now open.
下一個問題來自美國銀行美林(Bank of America-Merrill Lynch)的 Sumant Kulkarni。您的線路已開通。
- Analyst
- Analyst
Thanks for taking my question. Mike, this one's for you. With the current asset base that you have, how should we conceptually think about longer term top- and bottom-line growth on an organic basis, that's assuming Valeant doesn't have to do or want to do any more acquisitions at all?
謝謝讓我提問。Mike,這題是問您的。以您目前的資產基礎來看,如果假設 Valeant 完全不需要、也不想再做任何收購,我們在概念上應如何看待長期的有機營收(top line)與獲利(bottom line)成長?
- Chairman and CEO
- Chairman and CEO
I think outside the US, again, I think most of our emerging markets are just going to grow, in demographics. And we are assuming that at some point the US dollar weakens against those. I think those will be strong growth drivers for many years ahead. I think that countries like Western Europe, Canada and Australia, other developed markets, we're assuming low single-digit growth over the longer term. Those businesses compared to most pharmaceutical companies are disproportionately smaller for us and that's not by accident.
我認為在美國以外,重申一次,我們多數新興市場將會因人口結構而自然成長。而我們也假設在某個時間點美元會相對那些貨幣走弱。我認為這些將在未來許多年成為強勁的成長驅動力。至於西歐、加拿大、澳洲等其他已開發市場,我們長期假設是低個位數成長。相較於多數製藥公司,這些業務在我們的占比不成比例地更小,而這並非偶然。
If I look in the US, again, in dermatology I think, given our prowess in terms of our development and the pipeline that we have, we would continue to expect strong growth. It may not always be double digit but certainly high single digit. But for the foreseeable future, I think double digit.
如果看美國市場,同樣地,在皮膚科方面,我認為憑藉我們在研發上的能力以及現有的產品管線,我們仍預期會有強勁成長。不一定永遠是雙位數,但肯定是高個位數。不過在可預見的未來,我認為會是雙位數。
I think in terms of ophthalmology, contact lenses our only constraint to actually gaining share right now is manufacturing capacity. Unfortunately, it takes time to get that manufacturing capacity on-board. The silver lining is it means that we should be growing in contact lenses just bringing out manufacturing and some new products that we have for the next five years-plus, not only in the US, but around the world. So, I think that piece of the business has great growth prospects for a very long time.
在眼科方面,隱形眼鏡業務目前我們唯一限制市占提升的因素是製造產能。不幸的是,導入這些製造產能需要時間。好的一面是,這代表未來五年以上,我們僅靠擴充產能以及推出一些新產品,就應能推動隱形眼鏡成長,不僅在美國,也在全球。因此,我認為這塊業務在很長一段時間內都有很好的成長前景。
If I think of surgical, the same thing. We still have small shares. We have been gaining share. The cataract surgery market has flattened. It's actually shrunk this year in this country. There's lots of speculation why, including the recent changes to healthcare reimbursement through the government programs where people have to pay a higher piece of cash.
如果看手術相關業務,也是同樣情況。我們的市占仍然不高。我們一直在提升市占。白內障手術市場已趨於持平。今年在這個國家實際上還萎縮了。外界對原因有很多揣測,包括近期政府計畫下醫療給付(reimbursement)變更,導致民眾需要自付更高比例的現金。
But you can only delay cataract surgery for like 9 to 12 months and then after that people that need it can't drive anymore, whatever. So, we do expect the organic growth of the business to flip around.
但白內障手術最多只能延後大約 9 到 12 個月,之後需要手術的人就無法再開車之類的。因此,我們確實預期這項業務的有機成長會出現反轉回升。
And over the long term that business should grow 5% a year. So our job is to just continue to take share. Again, we have a number of products in our pipeline and I think that B+ L is doing very well in the surgical area. So we feel good about that.
而從長期來看,那項業務應該每年成長 5%。所以我們的工作就是持續擴大市占。再說一次,我們的產品線管線中有多項產品,我認為 B+L 在外科領域表現非常好。因此我們對此感到很有信心。
I think Salix, even with the products we have, we have strong growth prospects for five-plus years. And as Ari said we will be working to bring new products to market. And ophthalmology Rx, again, assuming we get approvals for products like Vesneo and Luminesse, that should provide some growth drivers. But we need to strengthen that pipeline, as well.
我認為 Salix,即使以我們現有的產品來看,未來五年以上仍有強勁的成長前景。而且如 Ari 所說,我們會努力把新產品推向市場。另外,眼科處方藥(ophthalmology Rx)方面,同樣地,假設我們能取得像 Vesneo 和 Luminesse 這類產品的核准,應可提供一些成長動能。但我們也需要強化那條產品管線。
It's a long way of saying that I think we feel quite good about our growth prospects for the next four or five years even if we were to do no more acquisitions. But I think the case of us doing no more acquisitions is a highly unlikely one.
長話短說,我想即使我們不再進行任何併購,我們對未來四到五年的成長前景仍然相當有信心。但我認為我們完全不再做任何併購的情況極不可能發生。
Operator
Operator
Your next question comes from the line of Umer Raffat from Evercore ISI. Your line is now open.
下一個問題來自 Evercore ISI 的 Umer Raffat。您的線路已開通。
- Analyst
- Analyst
Hi. Thanks for taking my questions. I have a few, if I may. First, in 3Q 2015 -- or actually let's do it on a year-to-date basis -- for the year to date, US pharma business is up 24% in price, 17% in volume. If you take out the neuro/other, what does that look like for price to volume? That's first.
嗨。謝謝讓我提問。如果可以的話,我有幾個問題。首先,在 2015 年第三季——或者其實我們用年初至今(YTD)來看——年初至今,美國製藥業務價格上升 24%,銷量上升 17%。如果把神經/其他(neuro/other)排除,價格與銷量的變化會是什麼樣?這是第一個問題。
Secondly, what do gross margins for the Company look like if neuro/other were to be divested?
第二,如果神經/其他被剝離,公司整體的毛利率會是什麼樣?
Number three, there's a slide that talks about growth to net disclosures. I really appreciate that. One of the products on there is Atralin, which took a 61% gross price increase, but less than 1% net increase. So, my question is, why even do that increase? Just want to understand how you think about that.
第三,有一張投影片談到「成長到淨額」(growth to net)的揭露。我非常感謝這點。其中一個產品 Atralin,名目(gross)價格上調 61%,但淨額(net)增幅不到 1%。所以我的問題是,為什麼還要做那樣的調價?只是想了解你們是如何思考這件事的。
And then, finally, Nitropress was $35 million this quarter versus $60 million last quarter or the quarter before. So, I just want to understand the trend there. Thank you.
最後,Nitropress 本季是 3,500 萬美元,而上一季或前一季是 6,000 萬美元。所以我想了解那裡的趨勢。謝謝。
- Chairman and CEO
- Chairman and CEO
I'm sorry, the first question, Umer? 24% and 17%, what would it have been without neuro? The second one, were you asking about gross margins?
抱歉,第一個問題是什麼,Umer?24% 和 17%,如果沒有神經(neuro)會是多少?第二個,你是在問毛利率嗎?
- Analyst
- Analyst
Yes, gross margin for the Company.
是的,公司毛利率。
- Chairman and CEO
- Chairman and CEO
Okay. So, let's go in reverse. Nitropress, I think it had -- in first quarter is when we had that large number. I think at that point -- we tried to be clear on the call -- that that was a disproportionate quarter because the inventories were basically depleted out in the market. So, it represented more than a quarter's worth of sales. That being said, the product is declining but it's not declining at the rate if you take the first quarter.
好的。那我們倒著回答。Nitropress,我想第一季是我們出現那個較大數字的時候。我想當時——我們在電話會議上也試著說清楚——那是一個不成比例的季度,因為市場上的庫存基本上已經被消化殆盡。所以它代表的不只是一個季度的銷售量。話雖如此,該產品確實在下滑,但如果把第一季納入比較,它的下滑速度並沒有那麼快。
Atralin at 60%, honestly that was probably a mistake and I think we've talked to our team there. So, we would not do that again because it makes no sense, as you point out, Umer. So that one's on us.
Atralin 調價 60%,老實說那可能是個錯誤,我想我們也已經和那邊的團隊談過。所以我們不會再那樣做,因為正如你指出的,Umer,那樣做沒有意義。這點是我們的問題。
In terms of neuro gross margins, actually they'll improve. If we didn't have neuro they would improve because a number of those products are partnered where we pay high royalties, like Xenazine. In total, the gross margins in neuro are not that good. So, that actually helps.
至於神經(neuro)的毛利率,其實會改善。如果沒有神經業務,毛利率會提升,因為其中不少產品是合作夥伴模式,我們需要支付較高的權利金,例如 Xenazine。整體而言,神經業務的毛利率並不理想。所以剝離反而有幫助。
And I don't have the calculation in terms of -- but in terms of the price in derm and ophthalmology, it's probably 5%. It's all really neuro and other that's the big one. And all the growth in volume, if we didn't have neuro and other our volume would certainly be above 20%. Without neuro and other we'd have at least 20% volume and then we'd probably have about 5% price. So, we'd be growing at least 25%, and probably a little bit more.
至於——我手上沒有精確的計算——但就皮膚科與眼科的價格來看,大概是 5%。主要都是神經與其他(neuro and other)那一塊影響最大。而銷量的成長,如果沒有神經與其他,我們的銷量成長肯定會高於 20%。沒有神經與其他,我們至少會有 20% 的銷量成長,然後價格大概會有 5%。所以我們至少會成長 25%,而且可能還會再高一些。
Operator
Operator
Your next question comes from the line of Doug Miehm from RBC Capital Markets. Your line is now open.
下一個問題來自 RBC Capital Markets 的 Doug Miehm。您的線路已開通。
- Analyst
- Analyst
Thank you. Couple questions, as well. Number one, with respect to patient access and foundations, maybe you could walk us through how many foundations you fund. And of those foundations what proportion of their annual operating budget would you provide to them?
謝謝。我也有幾個問題。第一,關於病患可近性(patient access)與基金會(foundations),也許你可以帶我們了解一下你們資助多少個基金會。以及在那些基金會中,你們提供的資金大約占其年度營運預算的多少比例?
The second one just has to do with, if you were to split out the US neuro business, can you give us a sense of what EPS contribution or EBITDA contribution that business would have? And I'll leave it there.
第二個問題是,如果把美國神經業務拆分出來,你們能否讓我們大致了解該業務對 EPS 或 EBITDA 的貢獻會是多少?我就問到這裡。
- Head of IR
- Head of IR
Why don't you concentrate on just a couple right now. We're trying to get through everybody. So, why don't we answer the --.
你現在先專注在幾個問題就好。我們想讓每個人都能問到。所以我們先回答——。
- Chairman and CEO
- Chairman and CEO
Pick your two favorite.
挑你最喜歡的兩個。
- Analyst
- Analyst
Just the foundations, just elaborate on that.
就基金會那題,請再多說明一下。
- Chairman and CEO
- Chairman and CEO
Okay. I don't have a precise number but it's like four or five, so it's a small number. We make sure, as we mentioned, that other companies are also contributing, or other organizations, at least, are also contributing. We do not want to be the only one to contribute.
好的。我沒有精確數字,但大概是四或五個,所以數量不多。我們會確保——如我們提到的——也有其他公司,或至少其他組織,也在出資。我們不希望自己成為唯一的出資者。
Again, we just give them the money and they do what they want to with that money. I don't want to give you a precise figure in terms of what percent of our funding because I don't have that and I don't want to guess. Next question.
同樣地,我們只是把錢給他們,他們想怎麼使用那筆錢就怎麼使用。至於我們資助占比是多少,我不想給你一個精確數字,因為我沒有資料,也不想猜測。下一個問題。
Operator
Operator
Your next question comes from Gregg Gilbert from Deutsche Bank. Your line is now open.
下一個問題來自 Deutsche Bank 的 Gregg Gilbert。您的線路已開通。
- Analyst
- Analyst
Yes, thanks. I had a quick comment and then a question. I just wanted to make the point that on slide 28 there's some important context missing in the footnotes, as you compare apples to oranges on the left versus the right. So, wanted to make that point.
是的,謝謝。我先簡短評論一下,然後提一個問題。我只是想指出,在第 28 張投影片的註腳中,當你把左邊和右邊做比較時,缺少了一些重要的背景脈絡,因為那是在拿蘋果比橘子。所以我想先提出這點。
But my question is about access to capital. Perhaps you could quantify the cost of the access you'd be accessing in this environment. Or is that not a relevant question in that you don't expect to access the market in the short term?
但我的問題是關於資本取得(access to capital)。也許你可以量化在目前環境下你們取得資金的成本。或者這不是個相關問題,因為你們預期短期內不會進入市場籌資?
- Chairman and CEO
- Chairman and CEO
I think the latter part is if we're going to reduce debt we don't want to increase debt first. I think we have access to our revolver which will go up and down but we don't plan on issuing new debt. If we have to retire some over time. But that's not in the short term. I think we're fortunate because the environment's not wonderful today, so basically the next five quarters we're looking to reduce debt, not take on any more debt.
我想是後者:如果我們要降低負債,我們不會先增加負債。我想我們可以動用循環信貸(revolver),額度會上上下下,但我們不打算發行新債。如果我們必須隨時間推進而償還一些債務。但那不是短期內的事。我想我們很幸運,因為今天的環境並不理想,所以基本上接下來五個季度我們的目標是降低負債,而不是再增加任何負債。
And Gregg, I'm sorry if some of the footnotes were not correct. We will correct those. We'll talk to you, we'll correct them and we'll put them up on our website.
Gregg,若有些註腳不正確,我很抱歉。我們會更正那些內容。我們會跟你聯繫、把它們更正,並放到我們的網站上。
Operator
Operator
Your next question comes from the line of Alan Ridgeway from Scotiabank. Your line is now open.
下一個問題來自豐業銀行(Scotiabank)的 Alan Ridgeway。您的線路現在已開通。
- Analyst
- Analyst
Hi, good morning. Just wondering if you could provide an update on contact lens business and the ULTRA manufacturing, and how many lines are online and what the outlook there is. Thanks.
嗨,早安。想請問您是否可以更新一下隱形眼鏡業務與 ULTRA 的製造情況,包括目前有多少條產線已上線,以及那邊的展望如何。謝謝。
- Company Group Chairman
- Company Group Chairman
Yes. We have line one operating already producing spherical ULTRAs. And line two we expect to have up and running probably in the April time frame. Line two is going to produce our toric lenses, line one will produce a combination of spherical and multifocals. And as we've said on previous calls, we've got lines three and four which we expect to be up and running sometime in the second half of next year.
好的。第一條產線已在運作,正在生產球面 ULTRA。第二條產線我們預期大概在四月左右可以啟動並投入運轉。第二條產線將生產我們的散光鏡片;第一條產線將生產球面與多焦點的組合。另外,如同我們在先前的電話會議中提到的,我們還有第三與第四條產線,預期會在明年下半年某個時間點啟動並投入運轉。
Operator
Operator
Your next question comes from the line of Jason Gerberry from Leerink Partners. Your line is now open.
下一個問題來自 Leerink Partners 的 Jason Gerberry。您的線路現在已開通。
- Analyst
- Analyst
Hi. Good morning. Thanks for taking my question. Just a quick question for Mike. Just curious as you think about divesting the neuro business, your thoughts on ability to fetch a tax inversion premium. I know that a number of mid-cap spec pharma players are looking for CNS assets and also looking to tax invert. So, curious your thoughts on the legislative landscape there and if those days are over or if you think that that may be an optimal way to maximize value for that part of the business. Thanks.
嗨。早安。謝謝讓我提問。給 Mike 一個簡短問題。想請教,當你們考慮剝離神經(neuro)業務時,你對於能否取得「稅務倒置(tax inversion)」溢價的看法是什麼。我知道有不少中型市值的專科製藥公司在尋找中樞神經系統(CNS)資產,同時也在尋求進行稅務倒置。所以想聽聽你對相關立法環境的看法:那樣的時代是否已經結束,或你認為那可能是使該業務部分價值最大化的最佳方式。謝謝。
- Chairman and CEO
- Chairman and CEO
I don't think the days are entirely over. I think in mergers of equals I do think that it's still quite possible. And it's an interesting concept that we have thought about, of spinning it off and eventually -- I think there would be a two-year time frame or something like that -- it could then merge with some other entities. Again, we're just trying to sort through the options and figuring out what will maximize value for our shareholders. But it's an interesting idea.
我不認為那樣的時代已完全結束。我認為在「對等合併(mergers of equals)」的情況下,仍然相當有可能。這確實是個有趣的概念,我們也想過:先把它分拆出去,然後最終——我想可能需要兩年的時間之類——之後再與其他實體合併。再次強調,我們只是正在梳理各種選項,並找出什麼能為股東創造最大價值。但這確實是個有趣的想法。
Operator
Operator
Our last question comes from Shibani Malhotra from Nomura Securities International. Your line is you now open.
我們最後一個問題來自野村證券國際(Nomura Securities International)的 Shibani Malhotra。您的線路現在已開通。
- Analyst
- Analyst
Thanks for taking the follow-up. Mike, on your commentary regarding pricing and the change in environment, et cetera, we understand the press and the media has gone after Valeant for some of the price increases you've taken. But in the larger scheme of things, by talking about not doing such deals anymore, et cetera, aren't you just validating the concerns the media has?
謝謝讓我追問。Mike,關於你對定價以及環境變化等的評論,我們理解媒體與新聞對 Valeant 先前的一些漲價行為提出了批評。但從更宏觀的角度來看,當你談到不再做這類交易等等時,你不就是在印證媒體所擔憂的問題嗎?
Can you talk a bit about what was happening in some of these markets where you took the price increases and what would have happened if you didn't buy those assets? We could have seen products just not being manufactured anymore.
你能否談談在你們進行漲價的某些市場中,當時發生了什麼?以及如果你們沒有收購那些資產,會發生什麼?我們可能會看到某些產品乾脆不再被製造。
- Chairman and CEO
- Chairman and CEO
I think that we're pragmatic and in the end we'd rather focus our time on righting our business. That's what we enjoy doing the most. Again, in terms of our acquisitions, as I mentioned earlier, only a very few of them were ones where we thought that assets were mispriced, where they actually were not being priced at the value they delivered to the healthcare system.
我認為我們是務實的,最後我們寧可把時間放在把公司經營好。那是我們最喜歡做的事。再說一次,就我們的併購而言,如我先前提到的,只有極少數是我們認為資產被錯誤定價的案例,也就是它們的定價其實沒有反映其對醫療體系所帶來的價值。
And I agree with you. If people are not able to price products at where they -- at the right -- it's not good for long-term markets because then you will not get more competitors in. It's interesting, a lot of our price increases that we took were on products where generics are available. Over 60% of our neuro products. So, other products, generic equivalents are available. And if doctors want to think those generics are of the same quality as the branded products, they're going to write those. So, I think if there's generics on the market I don't know why there should be any restriction on pricing.
而且我同意你的看法。如果人們無法把產品定價在——在正確的——水準,長期而言對市場並不好,因為那樣就不會吸引更多競爭者進入。有趣的是,我們許多的漲價其實是發生在已有學名藥可用的產品上。我們超過 60% 的神經產品都是如此。因此,其他產品也有學名藥等效品可用。如果醫師認為那些學名藥的品質與品牌藥相同,他們就會開立那些學名藥。所以,我認為如果市場上已有學名藥,我不明白為什麼定價還需要受到任何限制。
So, I think I agree with your question. I think the prices that we took when there were mispriced assets were appropriate. But the field is very large and we'll just be pragmatic and why focus on areas of the business that is just going to create a lot of media stir. Because the attention moves away from, I think, the strong volume organic growth that we're getting in places like dermatology, ophthalmology, Salix, contact lenses, our OTC business which is growing 8%, and the focus moves away from them. So, I agree with your point, but we're just being pragmatic.
所以,我想我同意你的問題。我認為在資產被錯誤定價時,我們所採取的價格是適當的。但這個領域很大,而我們會務實行事,何必把焦點放在只會引發大量媒體騷動的業務領域上。因為那樣會讓注意力從——我認為——我們在皮膚科、眼科、Salix、隱形眼鏡、以及我們成長 8% 的 OTC 業務等領域所取得的強勁量的內生成長上移開,焦點就被轉移了。所以,我同意你的觀點,但我們只是務實行事。
All right, I think that's all the questions. We appreciate the large attendance on this call and we'll look forward to talking to you next quarter.
好的,我想問題就到這裡。感謝各位踴躍參與本次電話會議,我們期待在下個季度再與各位交流。
Operator
Operator
This concludes today's conference. You may now disconnect.
今天的電話會議到此結束。您現在可以掛線。